<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Celecoxib: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Celecoxib: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Celecoxib: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8847" href="/d/html/8847.html" rel="external">see "Celecoxib: Drug information"</a> and <a class="drug drug_patient" data-topicid="11923" href="/d/html/11923.html" rel="external">see "Celecoxib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708651"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious cardiovascular risk:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction (MI), and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use.</p>
<p style="text-indent:-2em;margin-left:2em;">Celecoxib is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Serious gastrointestinal risk:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at higher risk for serious GI events.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F148404"><span class="drugH1">Brand Names: US</span>
<ul>
<li>CeleBREX;</li>
<li>Elyxyb</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866267"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Celecoxib [DSC];</li>
<li>AG-Celecoxib;</li>
<li>APO-Celecoxib;</li>
<li>Auro-Celecoxib;</li>
<li>BIO-Celecoxib;</li>
<li>CeleBREX;</li>
<li>JAMP-Celecoxib;</li>
<li>M-Celecoxib;</li>
<li>Mar-Celecoxib;</li>
<li>MINT-Celecoxib;</li>
<li>NRA-Celecoxib;</li>
<li>PMS-Celecoxib;</li>
<li>PMSC-Celecoxib;</li>
<li>Priva-Celecoxib [DSC];</li>
<li>RIVA-Celecox;</li>
<li>SDZ Celecoxib [DSC];</li>
<li>TARO-Celecoxib</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1004282"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Nonsteroidal Anti-inflammatory Drug (NSAID), COX-2 Selective</span></li></ul></div>
<div class="block dop drugH1Div" id="F4028614"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7bfa6a19-11be-4097-9456-7c7ce2ad756d">Juvenile idiopathic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Juvenile idiopathic arthritis (JIA):</b>
<b>Note:</b> Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">≥10 kg to ≤25 kg: Oral: 50 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;25 kg: Oral: 100 mg twice daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51084393"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥2 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">Baseline:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild or moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling; however, since &lt;1% of the drug is excreted in the urine, dosage adjustment is not necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10749518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10749518'])">Ref</a></span>). Based on unpublished data, AUC was ~40% <i>lower</i> in adult patients with chronic renal insufficiency (GFR 35 to 60 mL/minute) compared with subjects with normal renal function due to a higher apparent clearance.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">Advanced renal disease: Use is not recommended; however, if celecoxib treatment cannot be avoided, monitor renal function closely.</p>
<p style="text-indent:-2em;margin-left:2em;">During therapy: Abnormal renal function tests (persistent or worsening): Discontinue use.</p></div>
<div class="block dohp drugH1Div" id="F51084394"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥2 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate hepatic impatient: Reduce dose by 50%; monitor closely.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe hepatic impairment: Use is not recommended; has not been studied.</p></div>
<div class="block doa drugH1Div" id="F148409"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8847" href="/d/html/8847.html" rel="external">see "Celecoxib: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Avoid or use with caution in patients at risk for or with existing cardiovascular disease, GI disease, kidney impairment, chronic liver disease, or a bleeding diathesis due to greater risk for adverse events. Consider administering in combination with a proton pump inhibitor in patients at risk for GI bleeding (eg, taking dual antiplatelet therapy or an anticoagulant, ≥60 years of age, high celecoxib doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21060077','lexi-content-ref-19017521']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21060077','lexi-content-ref-19017521'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Use the lowest effective dose for the shortest duration of time.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9c28c7a4-d701-4dda-9ca7-b4ba7882a2bb">Acute pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute pain (monotherapy or as an adjunctive agent): Oral: </b>Initial: 400 mg, followed by 200 mg approximately 12 hours later, if needed, on day 1; thereafter, 200 mg twice daily as needed or scheduled; maximum daily maintenance dose: 400 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). In select patients (eg, advanced age, comorbidity), some experts may initiate at 100 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Portenoy.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Portenoy.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="462a3a59-e36e-4308-9661-36c83a515c19">Anti-inflammatory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anti-inflammatory (eg, for arthritis associated with inflammatory rheumatic disease</b>): <b>Oral:</b> Initial: 200 mg once daily <b>or</b> 100 mg twice daily; may increase to a maximum of 200 mg twice daily for several weeks during a disease flare until the flare resolves.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a95f7bf7-e7b2-4183-a9d6-2ca350b1202b">Dysmenorrhea</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dysmenorrhea:</b>
<b>Oral:</b> Initial: 400 mg, followed by an additional 200 mg approximately 12 hours later, if needed, on day 1; maintenance dose: 200 mg twice daily as needed; maximum daily maintenance dose: 400 mg/day. Begin at menses onset or 1 to 2 days prior to onset of menses for severe symptoms; usual duration: 1 to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19695387','lexi-content-ref-26224322','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19695387','lexi-content-ref-26224322','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a81184b-235e-4be1-8cc9-23a33b10cc65">Gout, treatment, acute flares</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gout, treatment, acute flares (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 400 mg, followed by 200 mg approximately 12 hours later on day 1, then continue 200 mg twice daily thereafter; maximum daily maintenance dose: 400 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22859357','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22859357','lexi-content-ref-Manu.1'])">Ref</a></span>). Initiate within 24 to 48 hours of flare onset; reduce dose as symptoms improve. Discontinue a few days after resolution of clinical signs (usual total duration: 5 to 7 days); longer duration may be required if therapy is delayed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gaffo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gaffo.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="94e2a3ee-a6a7-47a4-9a9e-1102ebb9cf5e">Migraine, acute treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, acute treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Limit use to ≤14 days per month to avoid medication-overuse headache (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34160823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34160823'])">Ref</a></span>). For use as monotherapy in mild to moderate attacks not associated with vomiting or severe nausea (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Schwedt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Schwedt.1'])">Ref</a></span>). Administration early in the course of a migraine attack, at the first sign of pain, may improve response to treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34160823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34160823'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 120 mg as a single dose. Maximum: 120 mg per 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33658842','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33658842','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="de72da14-7984-4455-9145-f85bde10917f">Osteoarthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoarthritis: </b>
<b>Oral:</b> 200 mg once daily <b>or</b> 100 mg twice daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991214"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥60 mL/minute: No dosage adjustment necessary (&lt;1% of the drug excreted in the urine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10749518','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10749518','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;30 to &lt;60 mL/minute: No dosage adjustment necessary (&lt;1% of the drug excreted in the urine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10749518','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10749518','lexi-content-ref-Expert.DOR'])">Ref</a></span>). However, use the lowest effective dose for the shortest duration possible. Use of analgesics other than nonsteroidal anti-inflammatory drugs (NSAIDs) or topical NSAIDs may be preferred. Avoid use in patients at high risk for acute kidney injury (ie, volume depleted, hypotensive, elderly, or taking concurrent nephrotoxic medications) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32479922','lexi-content-ref-KDIGO.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32479922','lexi-content-ref-KDIGO.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≤30 mL/minute: Avoid use due to increased risk of acute kidney injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1'])">Ref</a></span>); Use of analgesics other than NSAIDs or topical NSAIDs are preferred. However, in select patients where alternatives are not effective, after careful assessment of risks versus benefits, use of celecoxib may be considered; use the lowest effective dose for the shortest duration possible with close monitoring of kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzable (high protein binding, large V<sub>d</sub>): Avoid use, as patients with end-stage kidney disease may be at increased risk for bleeding (eg, GI), cardiovascular adverse effects, and loss of residual kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12900801','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12900801','lexi-content-ref-Expert.DOR'])">Ref</a></span>). However, in select patients after careful assessment of risks versus benefits, use of celecoxib may be considered; use the lowest effective dose for the shortest duration possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27881247','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27881247','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzable (high protein binding, large Vd): Avoid use, as patients with end-stage kidney disease may be at increased risk for bleeding (eg, GI), cardiovascular adverse effects, and loss of residual kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12900801','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12900801','lexi-content-ref-Expert.DOR'])">Ref</a></span>). However, in select patients after careful assessment of risks versus benefits, use of celecoxib may be considered; use the lowest effective dose for the shortest duration possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27881247','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27881247','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute kidney injury while on celecoxib therapy:</b> Discontinue use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988419"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary; AUC increased ~40% in mild hepatic impairment compared with healthy subjects.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment (Child-Pugh class B): Reduce dose by 50%.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">Abnormal liver function tests (persistent or worsening): Discontinue use.</p></div>
<div class="block arsc drugH1Div" id="F56788304"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of serious adverse cardiovascular (CV) events, including <b>acute myocardial infarction</b> (MI), <b>cerebrovascular accident</b>, and CV death. New-onset <b>hypertension</b> or <b>exacerbation of hypertension</b> may occur with NSAID use which may also contribute to an increased risk of CV events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29020251','lexi-content-ref-31937550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29020251','lexi-content-ref-31937550'])">Ref</a></span>). New-onset or exacerbation of <b>heart failure </b>may also occur with cyclooxygenase (COX)-2 selective NSAIDs (ie, coxibs), including celecoxib, and nonselective NSAIDs (eg, naproxen) resulting in an increased risk of hospitalizations for heart failure and death in patients with heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23747642','lexi-content-ref-FDA.2015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23747642','lexi-content-ref-FDA.2015'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Data collected by the Coxib and traditional NSAID Trialists’ (CNT) Collaborative has shown that use of COX-2 selective NSAIDs, including celecoxib, may increase the risk of major vascular events as compared to nonselective NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23726390']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23726390'])">Ref</a></span>); however, data from the PRECISION trial showed no difference with regards to risk between celecoxib, naproxen, or ibuprofen after a treatment duration of therapy of ~3 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27959716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27959716'])">Ref</a></span>). Additional trials and registry data are also conflicted with regards to the comparative risk of CV events among the COX-2 selective and nonselective NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15705456','lexi-content-ref-18541831','lexi-content-ref-15947398','lexi-content-ref-21224324','lexi-content-ref-12020179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15705456','lexi-content-ref-18541831','lexi-content-ref-15947398','lexi-content-ref-21224324','lexi-content-ref-12020179'])">Ref</a></span>). However, data in those with established heart disease consistently reveals an increased risk of harm with NSAID use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19171810','lexi-content-ref-24280110','lexi-content-ref-21555710','lexi-content-ref-24690187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19171810','lexi-content-ref-24280110','lexi-content-ref-21555710','lexi-content-ref-24690187'])">Ref</a></span>). The FDA states that there is insufficient data to determine if risk of MI or stroke is definitely higher or lower for any particular NSAID as compared to another (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2015'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; inhibition of COX-2 by NSAIDs results in a reduction in the production of prostaglandin I<sub>2</sub> (prostacyclin) in the vascular endothelium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11509629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11509629'])">Ref</a></span>); animal studies have shown that reduced prostacyclin activity may result in a predisposition to vascular injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11964481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11964481'])">Ref</a></span>). In addition, prostaglandins inhibit sodium resorption in the thick ascending loop of Henle and collecting tubule; therefore, a reduction in prostaglandin synthesis by NSAIDs may cause sodium and fluid retention and result in hypertension and decreased efficacy of diuretics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23747642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23747642'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; increased risk may be apparent within the first weeks following initiation of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2015','lexi-content-ref-21555710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2015','lexi-content-ref-21555710'])">Ref</a></span>); longer duration of therapy may further increase risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2015'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• ≥65 years of age</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (especially with regards to CV thrombotic risk) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2015'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of use and frequent use (eg, ≥22 days per month) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16534006','lexi-content-ref-FDA.2015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16534006','lexi-content-ref-FDA.2015'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting cardiovascular disease (CVD) or presence of risk factors for CVD, including use following coronary artery bypass graft surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19171810','lexi-content-ref-24280110','lexi-content-ref-27959716','lexi-content-ref-20031832','lexi-content-ref-21555710','lexi-content-ref-25710657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19171810','lexi-content-ref-24280110','lexi-content-ref-27959716','lexi-content-ref-20031832','lexi-content-ref-21555710','lexi-content-ref-25710657'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- <b>Note:</b> Relative risk appears to be similar in those with and without known CVD or risk factors for CVD; however, absolute incidence of serious CV thrombotic events appears to be higher in patients with known CVD or risk factors for CVD due to an increased baseline risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2015'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Gastrointestinal events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of serious gastrointestinal (GI) adverse events, including <b>gastrointestinal inflammation</b>, <b>gastrointestinal hemorrhage</b>, <b>gastrointestinal ulcer</b>, and <b>gastrointestinal perforation</b>; severity may range from asymptomatic to fatal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23726390','lexi-content-ref-28756267','lexi-content-ref-31937550','lexi-content-ref-29667211']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23726390','lexi-content-ref-28756267','lexi-content-ref-31937550','lexi-content-ref-29667211'])">Ref</a></span>). Selective cyclooxygenase (COX)-2 NSAIDs, including celecoxib, appear to be associated with a lower risk of significant GI adverse events as compared to nonselective NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11087881','lexi-content-ref-20638563','lexi-content-ref-10609815','lexi-content-ref-10979111','lexi-content-ref-10580457','lexi-content-ref-16490472']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11087881','lexi-content-ref-20638563','lexi-content-ref-10609815','lexi-content-ref-10979111','lexi-content-ref-10580457','lexi-content-ref-16490472'])">Ref</a></span>); the concomitant use of low-dose aspirin therapy may diminish the safety advantage of COX-2 selective NSAIDs over nonselective NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23726390','lexi-content-ref-20955443','lexi-content-ref-17556027']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23726390','lexi-content-ref-20955443','lexi-content-ref-17556027'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; inhibition of COX-1 by NSAIDs results in a reduction in the production of mucosal-protective prostaglandin E<sub>2</sub>). COX-2 selective NSAIDs may block COX-1 in the GI tract, albeit to a lesser degree as compared to nonselective NSAIDs, and therefore have the ability to cause damage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9626023','lexi-content-ref-10377455']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9626023','lexi-content-ref-10377455'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; GI events can occur at any time during use and without warning symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• ≥65 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20955443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20955443'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of use</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (eg, celecoxib 400 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17556027']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17556027'])">Ref</a></span>))</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of peptic ulcer disease and/or GI bleeding</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of agents known to increase the risk of GI bleeding (eg, aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20955443','lexi-content-ref-10979111']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20955443','lexi-content-ref-10979111'])">Ref</a></span>); anticoagulants, corticosteroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20955443','lexi-content-ref-2012355']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20955443','lexi-content-ref-2012355'])">Ref</a></span>); selective serotonin reuptake inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777151'])">Ref</a></span>))</p>
<p style="text-indent:-2em;margin-left:6em;">• Comorbid <i>Helicobacter pylori</i> infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16469671']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16469671'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Advanced liver disease/cirrhosis</p>
<p style="text-indent:-2em;margin-left:6em;">• Coagulopathy</p>
<p style="text-indent:-2em;margin-left:6em;">• Smoking</p>
<p style="text-indent:-2em;margin-left:6em;">• Consumption of alcohol</p>
<p style="text-indent:-2em;margin-left:6em;">• People with poor general health status</p>
<p style="text-indent:-2em;margin-left:6em;">• Small intestine damage: Small intestine bacterial overgrowth (SIBO), including SIBO induced by proton pump inhibitor therapy, may be associated with an increased risk of small intestine damage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28052268']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28052268'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of celecoxib may result in <b>anemia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22629288']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22629288'])">Ref</a></span>). Although no cases of drug-induced hemolytic anemia associated with celecoxib use have been reported, this adverse event has been reported with other nonsteroidal anti-inflammatory drugs (NSAIDs), including both non-selective and cyclooxygenase (COX)-2 selective agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25247621']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25247621'])">Ref</a></span>). While nonselective NSAIDs (eg, ibuprofen) may cause prolonged bleeding time and an increased risk for hemorrhage, COX-2 selective NSAIDS (eg, celecoxib), are less likely to result in abnormal platelet function or prolonged bleeding time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15668365','lexi-content-ref-15037526','lexi-content-ref-18359332','lexi-content-ref-11961179','lexi-content-ref-10664917','lexi-content-ref-19269020','lexi-content-ref-25710657','lexi-content-ref-27569276']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15668365','lexi-content-ref-15037526','lexi-content-ref-18359332','lexi-content-ref-11961179','lexi-content-ref-10664917','lexi-content-ref-19269020','lexi-content-ref-25710657','lexi-content-ref-27569276'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Anemia: Not clearly established; anemia may be due to occult or gross blood loss, or in some cases, drug-induced antibodies leading to autoimmune hemolysis.</p>
<p style="text-indent:-2em;margin-left:6em;">Prolonged bleeding time: Inhibition of COX-1 causes a decrease in the production of prostaglandins, prostacyclins, and thromboxanes, including thromboxane A2 (TxA2) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2724096']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2724096'])">Ref</a></span>). Therefore, patients exposed to NSAIDs, especially nonselective NSAIDs (eg, naproxen), may exhibit a decrease in platelet adhesion and aggregation and subsequent prolonged bleeding time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29891025','lexi-content-ref-18193919','lexi-content-ref-19269020','lexi-content-ref-1321554']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29891025','lexi-content-ref-18193919','lexi-content-ref-19269020','lexi-content-ref-1321554'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Onset</i>: Prolonged bleeding time: Rapid; suppression of platelet COX-1 activity occurs within hours of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15037526','lexi-content-ref-18359332']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15037526','lexi-content-ref-18359332'])">Ref</a></span>). In patients receiving antithrombotic therapy after myocardial infarction, the use of NSAIDs, including COX-2 selective NSAIDs (eg, celecoxib), has been associated with an increased risk of bleeding and excess thrombotic events even after short-term treatment (eg, &lt;3 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25710657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25710657'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:8em;">• Bleeding events:</p>
<p style="text-indent:-2em;margin-left:10em;">- Preexisting coagulation disorders</p>
<p style="text-indent:-2em;margin-left:10em;">- Concomitant use of agents known to increase the risk of bleeding (eg, anticoagulants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15668365']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15668365'])">Ref</a></span>); antithrombotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25710657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25710657'])">Ref</a></span>); antiplatelet agents [eg, aspirin, clopidogrel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11793622']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11793622'])">Ref</a></span>)]; selective serotonin reuptake inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777151'])">Ref</a></span>); or serotonin norepinephrine reuptake inhibitors)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of nonsteroidal anti-inflammatory drugs (NSAIDs), including celecoxib, may result in mild and transient transaminase elevations. The incidence of hepatic adverse events appears similar between celecoxib, naproxen, and ibuprofen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19530981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19530981'])">Ref</a></span>); diclofenac exhibits a higher rate of hepatotoxic events as compared to other NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29568654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29568654'])">Ref</a></span>). Rarely, use of celecoxib has resulted in acute <b>hepatitis</b> and drug-induced liver injury (DILI) with a hepatocellular, cholestatic, or mixed pattern of liver injury; celecoxib-induced liver injury requiring liver transplantation has been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19701976','lexi-content-ref-30449626','lexi-content-ref-20582911','lexi-content-ref-11470953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19701976','lexi-content-ref-30449626','lexi-content-ref-20582911','lexi-content-ref-11470953'])">Ref</a></span>). The pattern of celecoxib-induced liver injury may resemble sulfonamide-induced livery injury (ie, short latency and abrupt onset) and cross-reactivity has been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28795997']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28795997'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; some cases may exhibit immunoallergic features similar to sulfonamide-induced liver injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28795997']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28795997'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: DILI: Varied; cases with immunoallergic features may occur after a short duration of treatment (median: 12 days; range: 1 to 42), whereas cases without immunoallergic features may occur following prolonged use (6 months to 2 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28795997']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28795997'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:2em;margin-left:2em;">• Prior sulfonamide-induced liver injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28795997']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28795997'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immediate (eg, <b>anaphylaxis</b>, <b>urticaria/angioedema</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19299321','lexi-content-ref-17040369','lexi-content-ref-12789245','lexi-content-ref-11476468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19299321','lexi-content-ref-17040369','lexi-content-ref-12789245','lexi-content-ref-11476468'])">Ref</a></span>) and delayed <b>hypersensitivity reactions</b> have been reported with celecoxib. Delayed hypersensitivity reactions include mild reactions such as <b>maculopapular rash</b> and <b>fixed drug eruption</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15059110','lexi-content-ref-31376180','lexi-content-ref-17241570','lexi-content-ref-23026982','lexi-content-ref-11146365']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15059110','lexi-content-ref-31376180','lexi-content-ref-17241570','lexi-content-ref-23026982','lexi-content-ref-11146365'])">Ref</a></span>); severe cutaneous adverse reactions (SCARs) including <b>acute generalized exanthematous pustulosis </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15237269','lexi-content-ref-26488335']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15237269','lexi-content-ref-26488335'])">Ref</a></span>), <b>Stevens-Johnson syndrome/toxic epidermal necrolysis </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12222558','lexi-content-ref-12425513','lexi-content-ref-16180941','lexi-content-ref-14996398']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12222558','lexi-content-ref-12425513','lexi-content-ref-16180941','lexi-content-ref-14996398'])">Ref</a></span>) and <b>drug rash with eosinophilia and systemic symptoms </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18583892']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18583892'])">Ref</a></span>) have been documented. <b>Vasculitis of the skin</b> has also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15583611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15583611'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; immunologic. Immediate hypersensitivity reactions (eg, anaphylaxis, urticaria) are typically IgE-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Blumberg.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Blumberg.2020'])">Ref</a></span>). Delayed hypersensitivity reactions, including maculopapular eruptions, fixed drug eruption, and SCARs, are thought to be T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26339470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate hypersensitivity reactions: Rapid; occur within 1 hour of administration but may occur several hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17241570','lexi-content-ref-17040369']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17241570','lexi-content-ref-17040369'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed hypersensitivity reactions:</p>
<p style="text-indent:-2em;margin-left:8em;">Maculopapular reactions: Intermediate; typically occur 7 to 14 days after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17241570','lexi-content-ref-23026982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17241570','lexi-content-ref-23026982'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Other reactions (including SCARs): Varied; occur 1 to 8 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12222558','lexi-content-ref-26120552','lexi-content-ref-15237269','lexi-content-ref-NICE.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12222558','lexi-content-ref-26120552','lexi-content-ref-15237269','lexi-content-ref-NICE.2014'])">Ref</a></span>). Vasculitis of the skin has been reported 3 to 4 days after initiating therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15583611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15583611'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:6em;">• Selective cyclooxygenase (COX)-2 inhibitors (eg, celecoxib) are generally tolerated in patients with NSAID-exacerbated respiratory disease (NERD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21631520','lexi-content-ref-24388008','lexi-content-ref-30207919']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21631520','lexi-content-ref-24388008','lexi-content-ref-30207919'])">Ref</a></span>), patients with histories of isolated respiratory reaction to NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31100553']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31100553'])">Ref</a></span>), and in many patients with cutaneous reactions to NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15897671']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15897671'])">Ref</a></span>); however, cross-reactions may occur, especially in patients with histories of urticaria/angioedema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19940308','lexi-content-ref-24587953','lexi-content-ref-31100553']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19940308','lexi-content-ref-24587953','lexi-content-ref-31100553'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• There is limited published information regarding possible cross-reactivity between celecoxib and other sulfonamides (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12013363','lexi-content-ref-14510732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12013363','lexi-content-ref-14510732'])">Ref</a></span>). Cross-reactivity between celecoxib, a nonantibiotic sulfonamide, and antibiotic sulfonamides is unlikely to occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17156357','lexi-content-ref-31495421','lexi-content-ref-11330653','lexi-content-ref-12580647','lexi-content-ref-31022157']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17156357','lexi-content-ref-31495421','lexi-content-ref-11330653','lexi-content-ref-12580647','lexi-content-ref-31022157'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity among COX-2 inhibitors is not known, although there are reports of patients who have tolerated celecoxib following a reaction to etoricoxib (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19940308','lexi-content-ref-24661957','lexi-content-ref-31215658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19940308','lexi-content-ref-24661957','lexi-content-ref-31215658'])">Ref</a></span>). Cross-reactivity with nabumetone has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16542210']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16542210'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Kidney effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of nonsteroidal anti-inflammatory drugs (NSAIDs), including celecoxib, is associated with an increased risk of several kidney-specific effects: Hemodynamically-mediated<b> acute kidney injury </b>(AKI), <b>interstitial nephritis</b> (with or without nephrotic syndrome), and <b>renal papillary necrosis</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodynamically-mediated AKI: Hemodynamically-mediated AKI may occur following use of either cyclooxygenase (COX)-2 selective NSAIDs, including celecoxib, or nonselective NSAIDs (eg, naproxen) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32479922','lexi-content-ref-25439535','lexi-content-ref-17005625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32479922','lexi-content-ref-25439535','lexi-content-ref-17005625'])">Ref</a></span>); the risk may be greater with nonselective NSAIDs, especially indomethacin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26945352','lexi-content-ref-12014386','lexi-content-ref-23633310','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26945352','lexi-content-ref-12014386','lexi-content-ref-23633310','lexi-content-ref-10390124'])">Ref</a></span>). The risk of developing AKI is decreased upon discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15754275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15754275'])">Ref</a></span>). In patients who develop AKI, kidney function is likely to return to baseline following prompt discontinuation of the offending NSAID and supportive care (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10390124'])">Ref</a></span>); however, the mechanism of the damage and other concurrent factors can contribute to irreversibility.</p>
<p style="text-indent:-2em;margin-left:4em;">Acute interstitial nephritis (AIN) with or without nephrotic syndrome: Patients may develop NSAID-associated proteinuria combined with interstitial nephritis and varying degrees of kidney impairment; the “classic triad” of fever, rash, and eosinophilia is less commonly observed in NSAID-associated AIN than with antibiotic-induced AIN (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6363936','lexi-content-ref-31416889','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6363936','lexi-content-ref-31416889','lexi-content-ref-10390124'])">Ref</a></span>). In patients with concurrent nephrotic syndrome, kidney histology may reveal minimal change glomerulonephritis or membranous nephropathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6731494','lexi-content-ref-31416889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6731494','lexi-content-ref-31416889'])">Ref</a></span>). While use of celecoxib has been associated with this clinical picture (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12407655','lexi-content-ref-12046048']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12407655','lexi-content-ref-12046048'])">Ref</a></span>), the risk may be greatest with fenoprofen as compared to other NSAIDS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6731494','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6731494','lexi-content-ref-10390124'])">Ref</a></span>). Proteinuria generally improves within weeks following discontinuation; full recovery may require treatment and take up to a year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31416889','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31416889','lexi-content-ref-10390124'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Papillary necrosis: Chronic use of NSAIDs, including celecoxib, has resulted in the development of papillary necrosis which may occur in conjunction with chronic interstitial nephritis and progressive decline in glomerular filtration rate as a clinical syndrome known as analgesic nephropathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12523925','lexi-content-ref-12512867','lexi-content-ref-7306246']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12523925','lexi-content-ref-12512867','lexi-content-ref-7306246'])">Ref</a></span>). However, controversy exists on the degree to which NSAID use increases the risk for chronic kidney disease and analgesic nephropathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17410098','lexi-content-ref-32317121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17410098','lexi-content-ref-32317121'])">Ref</a></span>). Acute papillary necrosis may occur following NSAID overdose, especially in a setting of severe dehydration or intravascular volume depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21705120','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21705120','lexi-content-ref-10390124'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mechanism</i>:</p>
<p style="text-indent:-2em;margin-left:8em;">Hemodynamically-mediated AKI: Dose- and time-related; inhibition of COX-1 and COX-2 by NSAIDs results in a reduced production of nephroprotective prostaglandins and subsequent attenuation of renal vasodilation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3045551','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3045551','lexi-content-ref-10390124'])">Ref</a></span>). In addition, an increase in vasoconstriction of the afferent arteriole and impaired renal blood flow causes a reduction in the glomerular capillary pressure and filtration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25439535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25439535'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">AIN with or without nephrotic syndrome: Not clearly established. Following inhibition of COX-1 and COX-2 by NSAIDs, arachidonic acid is formed which may be further metabolized to leukotrienes via the lipoxygenase pathway; leukotrienes may increase vascular permeability within glomerular capillaries and peritubular capillaries and increase lymphocyte recruitment and activation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6731494','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6731494','lexi-content-ref-10390124'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Papillary necrosis: Time-related; exact mechanism is not clearly established; may be due to direct toxicity and/or inhibition of prostaglandin-mediated vasodilation resulting in ischemic necrosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25439535','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25439535','lexi-content-ref-10390124'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:8em;">AKI: Rapid; may occur within days of treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10390124'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">AIN with or without nephrotic syndrome: Varied; mean time of onset of ~5 months (range: 2 weeks to 18 months) has been described following use of nonselective NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6731494']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6731494'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:8em;">• AKI:</p>
<p style="text-indent:-2em;margin-left:10em;">- Preexisting kidney impairment</p>
<p style="text-indent:-2em;margin-left:10em;">- Chronic kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27853386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27853386'])">Ref</a></span>). <b>Note:</b> Higher cumulative doses (eg, celecoxib &gt;100 mg/day) may increase the risk for progression of chronic kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17349452']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17349452'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- ≥65 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31264694']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31264694'])">Ref</a></span>). <b>Note: </b>NSAID-associated AKI may also occur in pediatric patients, even at therapeutic doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23453549','lexi-content-ref-23360563']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23453549','lexi-content-ref-23360563'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hemodynamically-mediated AKI:</p>
<p style="text-indent:-2em;margin-left:10em;">- Preexisting conditions which result in decreased effective arterial circulation (ie, conditions where renal blood flow/renal perfusion may be dependent on prostaglandin-mediated vasodilation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32479922']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32479922'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:12em;">Volume depletion (eg, due to concomitant diuretic use, nausea, or vomiting)</p>
<p style="text-indent:-2em;margin-left:12em;">Heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15754275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15754275'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:12em;">Cirrhosis and ascites (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-447795']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-447795'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:12em;">Nephrotic syndrome</p>
<p style="text-indent:-2em;margin-left:10em;">- Concomitant use of diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or calcineurin inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29799625','lexi-content-ref-23299844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29799625','lexi-content-ref-23299844'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• AIN with or without nephrotic syndrome: Prior history of NSAID-induced nephrotic syndrome; recurrence has been described with a nonselective NSAID (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10879670']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10879670'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Papillary necrosis (acute):</p>
<p style="text-indent:-2em;margin-left:10em;">- Massive NSAID ingestion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10390124'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- Dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10390124'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- Intravascular volume depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21705120','lexi-content-ref-25439535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21705120','lexi-content-ref-25439535'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Papillary necrosis (chronic)/analgesic nephropathy: Chronic concomitant use of other analgesics (eg, aspirin, acetaminophen) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10390124'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F148373"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (&lt;2%), angina pectoris (&lt;2%), chest pain (&lt;2%), coronary artery disease (&lt;2%), edema (&lt;2%), exacerbation of hypertension (&lt;2%), palpitations (&lt;2%), peripheral edema (2%), tachycardia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (&lt;2%), cellulitis (&lt;2%), contact dermatitis (&lt;2%), dermatitis (&lt;2%), diaphoresis (&lt;2%), ecchymoses (&lt;2%), erythematous rash (&lt;2%), maculopapular rash (&lt;2%), pruritus (&lt;2%), skin changes (&lt;2%), skin photosensitivity (&lt;2%), urticaria (&lt;2%), xeroderma (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Albuminuria (&lt;2%), hot flash (&lt;2%), hypercholesterolemia (&lt;2%), hyperglycemia (&lt;2%), hypokalemia (&lt;2%), increased nonprotein nitrogen (&lt;2%), weight gain (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (4%), anorexia (&lt;2%), constipation (&lt;2%), diarrhea (6%), diverticulitis of the gastrointestinal tract (&lt;2%), dysgeusia (3%), dyspepsia (9%), dysphagia (&lt;2%), eructation (&lt;2%), esophagitis (&lt;2%), flatulence (2%), gastritis (&lt;2%), gastroenteritis (&lt;2%), gastroesophageal reflux disease (&lt;2%), hemorrhoids (&lt;2%), hiatal hernia (&lt;2%), increased appetite (&lt;2%), melena (&lt;2%), stomatitis (&lt;2%), tenesmus (&lt;2%), vomiting (&lt;2%), xerostomia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis (&lt;2%), dysuria (&lt;2%), hematuria (&lt;2%), urinary frequency (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (&lt;2%), thrombocythemia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes (&lt;3 x ULN: ≤6%), increased serum alkaline phosphatase (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema (&lt;2%), hypersensitivity reaction (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (&lt;2%), depression (&lt;2%), drowsiness (&lt;2%), fatigue (&lt;2%), hypertonia (&lt;2%), hypoesthesia (&lt;2%), migraine (&lt;2%), nervousness (&lt;2%), pain (&lt;2%), paresthesia (&lt;2%), peripheral pain (&lt;2%), vertigo (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (&lt;2%), increased creatine phosphokinase in blood specimen (&lt;2%), lower limb cramp (&lt;2%), myalgia (&lt;2%), synovitis (&lt;2%), tendinopathy (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Deafness (&lt;2%), tinnitus (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen (&lt;2%), increased serum creatinine (&lt;2%), nephrolithiasis (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Aggravated bronchospasm (&lt;2%), bronchitis (&lt;2%), bronchospasm (&lt;2%), cough (&lt;2%), dyspnea (&lt;2%), epistaxis (&lt;2%), flu-like symptoms (&lt;2%), laryngitis (&lt;2%), pharyngitis (2%), pneumonia (&lt;2%), rhinitis (2%), sinusitis (5%), upper respiratory tract infection (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Cyst (&lt;2%), fever (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Heart failure, pulmonary embolism, syncope, thrombophlebitis, ventricular fibrillation</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Gangrene of skin and/or subcutaneous tissue</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholelithiasis, esophageal perforation, gastrointestinal hemorrhage, hemorrhagic colitis, intestinal obstruction, intestinal perforation, pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia, cerebrovascular accident, suicidal tendencies</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Coronary thrombosis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, exfoliative dermatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Alveolar osteitis (post-oral surgery patients), gastrointestinal inflammation, gastrointestinal perforation, gastrointestinal ulcer</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute coronary syndrome (Kounis syndrome) (Regis 2015), deep vein thrombosis (Chan 2005), hypertension (Handler 2003), vasculitis (allergic) (Schneider 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Goeschke 2004; Lee 2016), Stevens-Johnson syndrome (La Grenade 2005), toxic epidermal necrolysis (Berger 2002; Friedman 2002; Perna 2003), vasculitis of the skin (Drago 2004)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoglycemia, hyponatremia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ageusia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, leukopenia, pancytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestasis (Chamouard 2005), hepatic failure (El Hajj 2009), hepatic necrosis, hepatitis (including cholestatic hepatitis) (Larrey 2019), jaundice (Chamouard 2005)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Chamberlin 2009), angioedema (Gagnon 2003), drug reaction with eosinophilia and systemic symptoms (Lee 2008), fixed drug eruption (Ammar 2019), nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anosmia, aseptic meningitis (Papaioannides 2004), intracranial hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Interstitial nephritis (Henao 2002), renal papillary necrosis (Akhund 2003)</p></div>
<div class="block coi drugH1Div" id="F148386"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, anaphylaxis, serious skin reactions) to celecoxib, sulfonamides, aspirin, other NSAIDs, or any component of the formulation; patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; use in the setting of CABG surgery.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Although the FDA-approved product labeling states this medication is contraindicated in patients with hypersensitivity to sulfonamide-containing drugs, the scientific basis of this cross-sensitivity has been challenged. See “Warnings/Precautions” for more detail.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Pregnancy (third trimester); women who are breast-feeding; severe, uncontrolled heart failure; active gastrointestinal ulcer (gastric, duodenal, peptic); active gastrointestinal bleeding; inflammatory bowel disease; cerebrovascular bleeding; severe liver impairment or active hepatic disease; severe renal impairment (CrCl &lt;30 mL/minute) or deteriorating renal disease; known hyperkalemia; use in patients &lt;18 years of age</p></div>
<div class="block war drugH1Div" id="F148370"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Medication-overuse headache: Acute migraine agents used more frequently than recommended (eg, &gt;14 days per month) may lead to worsening of headaches (medication-overuse headache). Symptoms include migraine-like daily headaches or a marked increase in frequency of migraine attacks. Withdrawal treatment may be necessary in the setting of overuse (AHS [Ailani 2021]; manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfonamide ("sulfa") allergy: The FDA-approved product labeling for many medications containing a sulfonamide chemical group includes a broad contraindication in patients with a prior allergic reaction to sulfonamides. There is a potential for cross-reactivity between members of a specific class (eg, two antibiotic sulfonamides). However, concerns for cross-reactivity have previously extended to all compounds containing the sulfonamide structure (SO<sub>2</sub>NH<sub>2</sub>). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides. T-cell-mediated (type IV) reactions (eg, maculopapular rash) are not well understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (SJS/TEN), some clinicians choose to avoid exposure to these classes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: The manufacturer's labeling states to not administer to patients with aspirin-sensitive asthma due to severe and potentially fatal bronchospasm that has been reported in such patients having received aspirin and the potential for cross reactivity with other NSAIDs. The manufacturer also states to use with caution in patients with other forms of asthma. However, in patients with known aspirin-exacerbated respiratory disease (AERD), the use of celecoxib initiated at a low dose with gradual titration in patients with stable, mild to moderate persistent asthma has been used without incident (Morales 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery: Gastric ulceration: Avoid chronic use of oral nonselective NSAIDs after bariatric surgery; development of anastomotic ulcerations/perforations may occur (Bhangu 2014; Mechanick 2020). Short-term use of celecoxib or IV ketorolac are recommended as part of a multimodal pain management strategy for postoperative pain (Chou 2016; Horsley 2019; Thorell 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cytochrome P450 isoenzyme 2C9 deficiency: Use with caution in patients with known or suspected deficiency of cytochrome P450 isoenzyme 2C9 (CYP 2C9*3/*3); poor metabolizers may have higher plasma levels due to reduced metabolism; consider reduced initial doses (initiate therapy with 25% to 50% of the lowest starting dose [eg, 50% to 75% dose reduction]) (CPIC [Theken 2020]). Alternate therapies should be considered in patients with juvenile idiopathic arthritis (JIA) who are poor metabolizers of CYP2C9.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with moderate hepatic impairment; dosage adjustment recommended. Not recommended for patients with severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Use with caution in pediatric patients with systemic-onset JIA; serious adverse reactions, including disseminated intravascular coagulation, may occur. Long-term cardiovascular risk in children has not been evaluated.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878376"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Consider alternate therapy in JIA patients who are identified to be CYP2C9 poor metabolizers. In a small pediatric study (n=4), the AUC of celecoxib was ~10 times higher in a child who was homozygous for CYP2C9*3, compared to children who were homozygous for the *1 allele (n=2) or who had the CYP2C9*1/*2 genotype; further studies are needed to determine if carriers of the CYP2C9*3 allele are at increased risk for cardiovascular toxicity or dose related adverse effects of celecoxib, especially with long-term, high-dose use of the drug (Stempak 2005).</p></div>
<div class="block foc drugH1Div" id="F148381"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">CeleBREX: 50 mg, 100 mg, 200 mg, 400 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 100 mg, 200 mg, 400 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Elyxyb: 120 mg/4.8 mL (4.8 mL) [contains alcohol, usp, levomenthol, peg-40 hydrog castor oil(cremophor rh40), polyoxyl/peg-35 castor oil(cremophor el)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Elyxyb: 120 mg/4.8 mL (4.8 mL) [contains alcohol, usp, levomenthol, peg-40 hydrog castor oil(cremophor rh40), polyoxyl/peg-35 castor oil(cremophor el); peppermint flavor]</p></div>
<div class="block geq drugH1Div" id="F148366"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F148388"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (CeleBREX Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $5.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $11.44</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $18.76</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $28.15</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Celecoxib Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $2.14 - $2.16</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.33 - $4.62</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $0.36 - $7.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $0.81 - $11.37</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Elyxyb Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120MG/4.8ML (per mL): $36.45</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866268"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">CeleBREX: 100 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">CeleBREX: 200 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 200 mg</p></div>
<div class="block admp drugH1Div" id="F52612390"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Lower doses may be administered without regard to meals (may administer with food to reduce GI upset); larger doses should be administered with food to improve absorption. Capsules may be swallowed whole or the entire contents emptied onto a teaspoon of cool or room temperature applesauce and ingested immediately with water. The sprinkled contents of the capsule on applesauce may be stored under refrigeration for up to 6 hours.</p></div>
<div class="block adm drugH1Div" id="F4028615"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:2em;">May be administered without regard to meals.</p>
<p style="text-indent:-2em;margin-left:2em;">Capsules: May be swallowed whole or the entire contents emptied onto a teaspoon of cool or room temperature applesauce and administered immediately with water. The contents of the capsules sprinkled onto applesauce may be stored under refrigeration for up to 6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution: Administer full dose directly from bottle. Administer partial dose with a calibrated measuring device (not a household teaspoon or tablespoon).</p></div>
<div class="block sts drugH1Div" id="F148399"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Do not refrigerate or freeze. Discard unused portion.</p></div>
<div class="block meg drugH1Div" id="F7874407"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:-2em;margin-left:2em;">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">NSAIDs: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2018%2F020998s050lbl.pdf%23page%3D21&amp;token=zTWA%2BhOn%2B4CoBhjnZljps9NviB1hQS4hKqLAFs73wmOaAkcNZuI4VWU0HaUvvqqpRyKkCLlGPWN6%2BsZKcFTtwpA48TovFTi2B%2BguKFks%2BlOrl01i8oL9vPpgyzmxPQMj&amp;TOPIC_ID=12999" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020998s050lbl.pdf#page=21</a></p></div>
<div class="block usep drugH1Div" id="F53565960"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Relief of signs and symptoms of juvenile idiopathic arthritis (JIA) (FDA approved in ages ≥2 years weighing ≥10 kg); relief of signs and symptoms of osteoarthritis, adult rheumatoid arthritis, and ankylosing spondylitis (FDA approved in adults); management of acute pain (FDA approved in adults); treatment of primary dysmenorrhea (FDA approved in adults); acute treatment of migraine with or without aura (Elyxyb: FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F148446"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">CeleBREX may be confused with CeleXA, Cerebyx, Cervarix, Clarinex</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F148430"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C9 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2D6 (weak)</p></div>
<div class="block dri drugH1Div" id="F148375"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acemetacin: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of GI bleeding may be increased with this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpelisib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aspirin: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). Management: Concurrent use of aspirin at doses beyond cardioprotective levels is not recommended.  While concurrent use of low-dose aspirin with a COX-2 inhibitor is permissable, patients should be monitored closely for signs/symptoms of GI ulceration/bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bemiparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Bemiparin.  Management: Avoid concomitant use of bemiparin and nonsteroidal anti-inflammatory agents (NSAIDs) due to the increased risk of bleeding. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (eg, hypertension) during concomitant therapy with NSAIDs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inducers (Moderate): May decrease the serum concentration of Celecoxib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inhibitors (Moderate): May increase the serum concentration of Celecoxib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may enhance the thrombogenic effect of Estrogen Derivatives. Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may increase the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Heparin.  Management: Decrease the dose of heparin or nonsteroidal anti-inflammatory agents (NSAIDs) if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketorolac (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Ketorolac (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.  Management: Consider reducing the lithium dose when initiating a NSAID. Monitor for increased lithium therapeutic/toxic effects if a NSAID is initiated/dose increased, or decreased effects if a NSAID is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents.  Management: Monitor for evidence of kidney injury or decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concurrent use in CHF or cirrhosis. Concomitant use of bumetanide with indomethacin is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Nonsteroidal Anti-Inflammatory Agents may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Sulfonamides may enhance the adverse/toxic effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetFORMIN: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of MetFORMIN. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.  Management: Avoid coadministration of higher dose methotrexate (such as that used for the treatment of oncologic conditions) and NSAIDs. Use caution if coadministering lower dose methotrexate and NSAIDs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mifamurtide: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftazone: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk for gastrointestinal toxicity is increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of gastrointestinal (GI) toxicity is increased. Management: Coadministration of systemic nonsteroidal anti-inflammatory drugs (NSAIDs) and topical NSAIDs is not recommended. If systemic NSAIDs and topical NSAIDs, ensure the benefits outweigh the risks and monitor for increased NSAID toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenylbutazone: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Salts: Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium Salts. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Avoid coadministration of pralatrexate with nonsteroidal anti-inflammatory drugs (NSAIDs). If coadministration cannot be avoided, closely monitor for increased pralatrexate serum levels or toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostaglandins (Ophthalmic): Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Products: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tenofovir Products.  Management: Seek alternatives to these combinations whenever possible. Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose due to a potential risk of acute renal failure. Diclofenac appears to confer the most risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenoxicam: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: CYP2D6 Inhibitors (Weak) may increase the serum concentration of Thioridazine.  Management: Consider avoiding concomitant use of thioridazine and weak CYP2D6 inhibitors. If combined, monitor closely for QTc interval prolongation and arrhythmias. Some weak CYP2D6 inhibitors list use with thioridazine as a contraindication.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolperisone: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tolperisone. Specifically, the risk of hypersensitivity reactions may be increased. Tolperisone may enhance the therapeutic effect of Nonsteroidal Anti-Inflammatory Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of major adverse cardiac events (MACE), hemorrhagic stroke, ischemic stroke, and heart failure may be increased. Tricyclic Antidepressants may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triflusal: Nonsteroidal Anti-Inflammatory Agents may decrease the protein binding of Triflusal. Specifically, NSAIDs may decrease protein binding of the active Triflusal metabolite. Triflusal may decrease the protein binding of Nonsteroidal Anti-Inflammatory Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F148400"><span class="drugH1">Food Interactions</span>
<p style="text-indent:-2em;margin-left:2em;">Peak concentrations are delayed when taken with a high-fat meal. Management: Administer without regard to meals.</p>
<p style="text-indent:-2em;margin-left:4em;">Capsules: AUC is increased by 10% to 20% when taken with a high-fat meal.</p></div>
<div class="block rep_considerations drugH1Div" id="F49295131"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Nonsteroidal anti-inflammatory drugs (NSAIDs) may delay or prevent rupture of ovarian follicles. This may be associated with infertility that is reversible upon discontinuation of the medication. Consider discontinuing use in patients having difficulty conceiving or those undergoing investigation of fertility.</p>
<p style="text-indent:0em;margin-top:2em;">Based on available information, NSAIDs can be continued in patients with rheumatic and musculoskeletal diseases who are planning to father a child (ACR [Sammaritano 2020]).</p></div>
<div class="block pri drugH1Div" id="F148389"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">The use of nonsteroidal anti-inflammatory drugs (NSAIDs) close to conception may be associated with an increased risk of miscarriage due to cyclooxygenase-2 inhibition interfering with implantation (Bermas 2014; Bloor 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Birth defects have been observed following in utero NSAID exposure in some studies; however, data are conflicting (Bloor 2013). Nonteratogenic effects, including prenatal constriction of the ductus arteriosus, persistent pulmonary hypertension of the newborn, oligohydramnios, necrotizing enterocolitis, renal dysfunction or failure, and intracranial hemorrhage have been observed in the fetus/neonate following in utero NSAID exposure (Bermas 2014; Bloor 2013). Maternal NSAID use may cause fetal renal dysfunction leading to oligohydramnios. Although rare, this may occur as early as 20 weeks' gestation and is more likely to occur with prolonged maternal use. Oligohydramnios may be reversible following discontinuation of the NSAID (Dathe 2019; FDA 2020). In addition, nonclosure of the ductus arteriosus postnatally may occur and be resistant to medical management (Bermas 2014; Bloor 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal use of NSAIDs should be avoided beginning at 20 weeks' gestation. If NSAID use is necessary between 20 and 30 weeks' gestation, limit use to the lowest effective dose and shortest duration possible; consider ultrasound monitoring of amniotic fluid if treatment extends beyond 48 hours and discontinue the NSAID if oligohydramnios is found (FDA 2020). Because NSAIDs may cause premature closure of the ductus arteriosus, product labeling for celecoxib specifically states use should be avoided starting at 30 weeks' gestation.</p>
<p style="text-indent:0em;margin-top:2em;">Based on available information, NSAIDs can be continued during the first 2 trimesters of pregnancy in patients with rheumatic and musculoskeletal diseases; use in the third trimester is not recommended (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Treatment for migraine headaches in pregnant patients should be individualized (AHS [Ailani 2021]). The acute treatment of migraine headaches during pregnancy should be initiated with an agent other than an NSAID. If an NSAID is needed as second-line therapy, treatment should be limited to the second trimester and total duration of therapy should be no longer than 48 hours. An NSAID other than celecoxib may be preferred (ACOG 2022).</p>
<p style="text-indent:0em;margin-top:2em;">NSAIDs may be used as part of a multimodal approach to pain relief following cesarean delivery (ACOG 2019).</p></div>
<div class="block mopp drugH1Div" id="F53565959"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC; blood chemistry profile; occult blood loss; periodic liver function tests; renal function (urine output, serum BUN and creatinine); monitor efficacy (eg, in arthritic conditions: Pain, range of motion, grip strength, mobility, inflammation); observe for weight gain, edema; observe for bleeding, bruising; evaluate GI effects (abdominal pain, bleeding, dyspepsia); blood pressure (baseline and throughout therapy); cardiac ischemia in patients with a recent MI (avoid use in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events)</p>
<p style="text-indent:-2em;margin-left:2em;">JIA: Monitor for development of abnormal coagulation tests in patients with systemic-onset JIA</p></div>
<div class="block pha drugH1Div" id="F148369"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline"> Inhibits prostaglandin synthesis by decreasing the activity of the enzyme, cyclooxygenase-2 (COX-2), which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties. Celecoxib does not inhibit cyclooxygenase-1 (COX-1) at therapeutic concentrations. </p></div>
<div class="block phk drugH1Div" id="F148385"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption:</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: Prolonged due to low solubility.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Rapid (Pal 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub> (apparent):</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: Children and Adolescents ~7 to 16 years (steady-state): 8.3 ± 5.8 L/kg (Stempak 2002); Adults: ~400 L.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Adults: ~288 to 743 L (Pal 2017; manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~97% primarily to albumin; binds to alpha<sub>1</sub>-acid glycoprotein to a lesser extent.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP2C9; forms inactive metabolites (a primary alcohol, corresponding carboxylic acid, and its glucuronide conjugate).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability:</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: Absolute: Unknown.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: 144% (relative to capsule) (Pal 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: Children and Adolescents ~7 to 16 years (steady-state): 6 ± 2.7 hours (range: 3 to 10 hours) (Stempak 2002); Adults: ~11 hours (fasted).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Adults: 0.7 to 1 hour (Pal 2017; manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: Children: Median: 3 hours (range: 1 to 5.8 hours) (Stempak 2002); Adults: ~3 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Adults: 0.7 to 1 hour (Pal 2017; manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (~57% as metabolites, &lt;3% as unchanged drug); urine (27% as metabolites, &lt;3% as unchanged drug); primary metabolites in feces and urine: Carboxylic acid metabolite (73% of dose); low amounts of glucuronide metabolite appear in urine.</p></div>
<div class="block phksp drugH1Div" id="F51220827"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Capsule: AUC is approximately 40% lower in patients with a CrCl of 35 to 60 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Capsule: AUC is increased approximately 40% in patients with mild impairment (Child-Pugh class A) and 180% in patients with moderate impairment (Child-Pugh class B).</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: The AUC and C<sub>max</sub> following administration of a capsule contents sprinkled on applesauce were reported to be similar as administration of an intact capsule (Krishnaswami 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult (&gt;65 years of age): Capsule: C<sub>max</sub> is 40% higher and AUC is 50% higher.</p>
<p style="text-indent:-2em;margin-left:2em;">Race/ethnicity: Capsule: AUC is approximately 40% higher in Black patients compared with White patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F148392"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Algoxib | Arthrix | Arthromax | Celdol | Celebrex | Celecon | Celemac | Coxib | Gloxib | Movydia | Nexib | Qualcox | Revcox | Rumabrex</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Algitrat x | Algybrex | Celebrex | Celecoxib richet | Celemax | Coxel | Coxtenk | Niflam | Tisorek</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Celebrex | Celecoxib pfizer | Celecoxib ratiopharm</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo celecoxib | Blooms the chemist celecoxib | Celaxib | Celebrex | Celecoxib actavis | Celecoxib an | Celecoxib APOTEX | Celecoxib gh | Celecoxib rbx | Celecoxib sandoz | Celexi | Chemmart celecoxib | Kudeq | Noumed celecoxib | Terry white chemists celecoxib</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Acicox | Celecox-r | Celenta | Celox-r | Celoxib | Ciox | Cox B | Coxib | Cyclo-2 | Dicoxib | Ezy | Selecox</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Celebrex | Celecoxib ab | Celecoxib APOTEX | Celecoxib eg | Celecoxib sandoz | Celecoxib teva | Onsenal</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Celebid | Celebrex</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Aclexa | Algoxib | Celebrex | Celecoxib ecopharm | Coxi | Definax | Tevacoxib</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Celebra | Celecoxibe | Cibex | Coques | Dicoxibe | Ducox | Foxis</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Celebrex | Celecoxib actavis | Celecoxib axapharm | Celecoxib helvepharm | Celecoxib mepha | Celecoxib pfizer | Celecoxib sandoz | Celecoxib spirig hc | Celecoxib xiromed | Celecoxib zentiva</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Celebrex | Celecoxib sp | Celox-r | Inibrex</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Argium | Artrexib | Capsure | Celebra | Celebra fem | Celebra max | Celedox | Celerium | Celevitae | Coques | Coxdos | Coxel | Dolertab | Gesix | Nodocib | Valdyne</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Celebrex</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Artroxil | Atrixib | Cefinix | Celebrex | Celicob | Cicloxx | Colecoxib | Dilox | Flonar | Lexfin | Miodar | Sosedol</span>;</li>
<li>
<span class="countryCode">(CR)</span> <span class="country">Costa Rica</span><span class="countrySeparator">: </span><span class="drugName">Doloxene</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Aclexa | Celebrex | Celekoxib Mylan</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Celebrex | Celecaxiro | Celecox hexal | Celecoxib 1A pharma | Celecoxib abz | Celecoxib acino | Celecoxib actavis | Celecoxib AL | Celecoxib alembic | Celecoxib aurobindo | Celecoxib beta | Celecoxib heumann | Celecoxib micro labs | Celecoxib mylan | Celecoxib pfizer | Celecoxib puren | Celecoxib ratiopharm | Celecoxib stada | Celecoxib TAD | Celecoxib zentiva</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Algitrat | Artrox | Bicoxib | Celbib | Celebra | Celebrex | Celeco | Celecofran | Celeconav | Celecoxib mk | Celeflan | Coxal | Impedil | Maximus | Nexera | Revcox</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Algivex | Celebjar | Celebrex | Celecoxib la sante | Celeridan | Celevitae | Dolocox | Fullcox | Gesix | Julcox | Revibra</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Aclexa | Celebrex | Celecoxib accord</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Arythrex | Celeborg | Celebrex | Celecox | Celoxib | Rhuma max</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Artilog | Axatal | Celebrex | Celecoxib actavis | Celecoxib almus | Celecoxib Alter | Celecoxib amneal | Celecoxib APOTEX | Celecoxib cinfa | Celecoxib combix | Celecoxib kern pharma | Celecoxib Krka | Celecoxib mabo | Celecoxib macleods | Celecoxib mylan | Celecoxib normon | Celecoxib pensa | Celecoxib qualigen | Celecoxib ranbaxy | Celecoxib ratiopharm | Celecoxib sandoz | Celecoxib stada | Celecoxib tarbis | Celecoxib tecnigen | Celecoxib teva | Celecoxib vir | Celecoxib zentiva | Meticel | Onsenal | Oxibin</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Celofen | Unicelib</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Celebra | Celecoxib Krka | Celecoxib orion | Celecoxib pfizer | Celecoxib sandoz | Celecoxib stada | Onsenal</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Celebrex | Celecoxib arrow | Celecoxib biogaran | Celecoxib cristers | Celecoxib eg | Celecoxib mylan | Celecoxib pfizer | Celecoxib ranbaxy | Celecoxib sandoz | Celecoxib teva | Celecoxib zentiva | Onsenal</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Celebrex | Onsenal</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Aclarex | Celebrex</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo celecoxib | Apt celecoxib | Cecolex | Celcoxx | Celebrex | Celxib | Cobix | Eurobrex | Favocox | Keltrex | Selexib | Stadloric | Unibrex</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Aclexa | Celixib</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Aclexa | Celebrex</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Celcox | Celebrex | Celenox | Novexib</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Celebrex | Celecoxib actavis | Celecoxib Krka | Celecoxib rowex | Onsenal</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Celcox | Celebra</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alcox | Ce | Celact | Celcib | Celcox | Celebix | Celebrex | Celecap | Celedol | Celeheal | Celemax | Celetop | Celfast | Celib | Celicx | Celira | Celkob | Cib | Cobix | Colcibra | Coxib | Eloxib | Femcox | Icel | J flex | Orthocel | Ranselex | Revibra | Selcoxib | Sionara | Speshel | Zecoxib | Zycel</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Artilog | Celartrox | Celebrex | Celecoxib Alter | Celecoxib aurobindo | Celecoxib doc generici | Celecoxib eg | Celecoxib Krka | Celecoxib mylan pharma | Celecoxib pensa | Celecoxib pfizer | Celecoxib ranbaxy | Celecoxib sandoz | Celecoxib tecnigen | Celecoxib teva | Celecoxib zentiva | Coxiben | Onsenal | Solexa</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Celebrex | Flamex | Pedexa</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Celcoxx | Celdol | Celebib | Celebrex | Celenta | Celetor | Celex b | Cox B | Coxinhib | Lexib | Oxiceb | Sionara | Zycel</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Anacox | Ausbrex | Barocox | Bearcoxib | Brexib | C cox | C tlex | C trex | Cebicox | Cebucoxy | Cecob | Cecoc | Cecox | Cecoxia | Cecoxib | Celb | Celbesta | Celbic | Celbicoks | Celbicox | Celbit | Celbrec | Celbric | Celbrox | Celcobics | Celcobrex | Celcox | Celcoxbrex | Cele v | Celeb | Celebex | Celebrec | Celebrex | Celecl | Celeco | Celecob | Celecok | Celecop | Celecox | Celecoxin | Celecoxta | Celecsil | Celecxib | Celegen | Celelox | Celemed | Celemin | Celenogic | Celeon | Celepro | Celerox | Celes | Celetis | Celevis | Celewin | Celex | Celexib | Celexibe | Celexstar | Celextar | Celfen | Celibcox | Celleb | Cellox | Celox | Celsc | Celtib | Celvix | Celxib | Cenex | Cereamine | Cerebex | Cerebrin | Cerec | Cerecob | Cerescox | Cereupa | Cerex | Cerocoq | Cexib | Cexibre | Choa celecoxib | Cielcox | Cloxib | Cox 2 | Coxbito | Coxcare | Coxgreen | Coxib | Coxione | Coxnac | Coxren | Cricox | Cybrex | Delcox | Dongkwang celecoxib | Encox | Famcoxib | Genuone celecoxib | Hancox | Hulex | I celcoc | Ilyangbio celecoxib | J brex | J cox | Kelcoxib | Klicox | Laxib | Legolex | Medi c cox | Medibrex | Ncecox | Nelson celecoxib | Newbrex | Newcelcox | Pharma celecoxib | Picox | Samsung celecoxib | Tds celecoxib | Tucoxib | Unibrex | Varocox | Withucox | Yucox</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Celebrex | Coxicel | Selexib</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Celebib | Celebrex | Celecoxib arrow | Coxel | Normocoxib | Revcox</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Aclexa | Celebrex | Celecoxib accord | Celecoxib aurobindo | Celecoxib ranbaxy | Celecoxib zentiva</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Celebrex | Celecoxib eg | Onsenal</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Aclexa | Celebrex | Celecoxib accord | Celecoxib zentiva</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Celebrex | Celephi | Isox | Voxcib</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bienuex | Celebrex | Cinaron | Cortax | Delecon | Dropofex | Gruxno | Igef | Tiagorol | Xeletec</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Celebib | Celebrex | Geloxib | Hovid celecoxib | Rabirox | Revcox | Torcoxib | Zobrex</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Celecoxib sandoz | Celecoxx | Celeflox | Celopro | Flacoxto | Markoxib | Recoxib | Rhumacox | Xenobrex</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Celebrex | Celecoxib actavis | Celecoxib CF | Celecoxib mylan | Celecoxib sandoz</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Celebra | Celebrex | Celecoxib medical valley</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Celebrex | Celecoxib pfizer | Celostea</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Articox | Artrixib | Artromycin forte | Augesico | Blockten | C brex | Caditar | Celebrex | Celecoxine | Celecoxmek | Celemexin | Celepoxx | Celestal | Celestalip | Celevit | Celexia | Colcibra | Coques | Coxacib | Coxalgen | Coxicel | Coxiflam | Coxiluxx | Debrox | Diphacoxib | Dolibrex | Dorit | Larcox | Quilxib | Revibra | Sifacox | Thritex | Zipral</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Alcoxib | Argicox | Aubrex | Brecxib | Brexen | C flam | Capxibb | Celbex | Celcoxx | Celebrex | Celecorvic | Celecure | Celeflam | Celehan | Celence | Celerich | Celetor | Celevue | Celexib | Celix 200 | Celudex | Cofidec | Cox-2 | Coxapill | Coxbitor | Coxibet | Coxid | Coxidia | Coxiv | Coxoral | Coxsilv | Coxto | Coxtu | Coxzan | Dancoxib | Dialexib | Diaxib | Dolcelox | Ecox | Emicox | Euroflam | Execoxib | Flacoxto | Flamacox | Flamar | Geocoxib | Geoxcib | Goxib | Icox | Kairoxib | Lecoxigan | Lexib | Lincox | Nacoxib | Neocoxib | Occib | Paintab | Penxib | Pharex Celecoxib | Philicoxib | Provicoxib | Recosan | Reduflam | Rheuoxib | Saphlecox | Selecap | Swelcid | Trucox | Vicoxiv | Xelic</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Aflamoxib | Aimcoxib | Articoxib | Artiflex | Bixo | Calaxib | Celadon | Celart | Celbexx | Celebrex | Celecap | Celecomed | Celeeard | Celenor | Celetab | Celox | Celoxib | Celstar | Cewim | Cicxib | Cilavef | Coaxid | Cobix | Coixn | Conxib | Coxban | Coxicap | Cril | Cxib | Dancox | Dorsiflex | Geocoxib | Inicox | Invicox | Ixib | Kalixx | Koib | Koxibnel | Lecob | Lecox | Lezoxib | Max xib | Mifcoxib | Moveryl | Nuzib | Orthocel | Recoxib | Remicox | Rheuoxib | Rival | Sefecox | Seloxx | Xecoc | Xibocel | Xybie | Zeloxt</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Aclexa | Celebrex | Elecoxel | Onsenal | Zelsiglat</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Celebrex | Elyxyb</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Celebrex | Celecoxib Alter | Celecoxib bluepharma | Celecoxib Ciclum | Celecoxib cinfa | Celecoxib Fantex | Celecoxib Farmoz | Celecoxib Generis | Celecoxib Krka | Celecoxib Labesfal | Celecoxib mylan | Celecoxib Pentafarma | Celecoxib ratiopharm | Celecoxib sandoz | Celecoxib Tolife | Celecoxib zentiva | Solexa</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Celecoxib dallas | Eliflam | Eliflam forte | Gesix | Percalan</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Celcoxx | Celdol | Celebrex | Celetor | Coxicel | Flamex | Qualcox | Revcox | Selexib | Zyoxib</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Aclexa | Algoxib | Calidem | Celebrex | Celecoxib actavis | Celecoxib terapia | Celetor</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Celebrex | Celecoxib vial | Dilaxa | Rowcoxib | Simcoxib</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Cebo | Celebrex | Celect | Celoxib | Flamex | Oxibin | Pms celecoxib | Qualcox | Relif | Rigorixa</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Celebra | Celebrex | Celecoxib ebb | Celecoxib Krka | Celecoxib medical valley | Celecoxib orion | Celecoxib sandoz | Celecoxib stada | Onsenal</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Celebrex | Hovid celecoxib</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Celebrex</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Aclexa | Adaxib | Celebrex | Lectazib</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Celebrex | Celxib | Cybec | Mediccoxib | Painex | Rancelex | Zobrex</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Adybrex | Algibrex | Celebrex | Celoxx | Coxibrex | Inflacox | Inibrex | Inicox 2 | X back</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Celebrex | Celgyn</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cecolex | Cecoxii | Celebrex | Celecolen | Celecor | Celexib | Celofen | Ecopain | Relecox | Selexib | Sincoxib</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Celebrex | Celecoxib norton | Denoxib | Lekoxa | Ranselex | Zycel</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Unicelib | Zeecel | Zimcox | Zycel</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Ast-herix celecoxib | Celeb | Celebra | Celemax | Celexa | Celicox-2</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Celebrex | Cexb | Coabib | Coxiben</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Agilecox | Celosti | Ceozime | Coxirich | Doresyl | Ezelex | Foxicure | Gracox | Ikoxib | Locobile | Mibecerex | Paxicox | Sagacoxib | Vicoxib</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aclexa | Anabrex | Celebrex | Celecoxib ascendis | Celecoxib unicorn | Coxep | Coxib | Coxleon | Cyretib | Lexib</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Celofen | Colcibra | Unicelib</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-21060077">
<a name="21060077"></a>Abraham NS, Hlatky MA, Antman EM, et al; ACCF/ACG/AHA. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. <i>Circulation</i>. 2010;122(24):2619-2633. doi:10.1161/CIR.0b013e318202f701<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/21060077/pubmed" id="21060077" target="_blank">21060077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6731494">
<a name="6731494"></a>Abraham PA, Keane WF. Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. <i>Am J Nephrol</i>. 1984;4(1):1-6. doi:10.1159/000166764<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/6731494/pubmed" id="6731494" target="_blank">6731494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34160823">
<a name="34160823"></a>Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. <i>Headache</i>. 2021;61(7):1021-1039. doi:10.1111/head.14153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/34160823/pubmed" id="34160823" target="_blank">34160823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12523925">
<a name="12523925"></a>Akhund L, Quinet RJ, Ishaq S. Celecoxib-related renal papillary necrosis. <i>Arch Intern Med</i>. 2003;163(1):114-115. doi:10.1001/archinte.163.1.114<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/12523925/pubmed" id="12523925" target="_blank">12523925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15059110">
<a name="15059110"></a>Alonso JC, Ortega JD, Gonzalo MJ. Cutaneous reaction to oral celecoxib with positive patch test. <i>Contact Dermatitis</i>. 2004;50(1):48-49. doi:10.1111/j.0105-1873.2004.00271i.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/15059110/pubmed" id="15059110" target="_blank">15059110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12407655">
<a name="12407655"></a>Alper AB Jr, Meleg-Smith S, Krane NK. Nephrotic syndrome and interstitial nephritis associated with celecoxib. <i>Am J Kidney Dis</i>. 2002;40(5):1086-1090. doi:10.1053/ajkd.2002.36349<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/12407655/pubmed" id="12407655" target="_blank">12407655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29891025">
<a name="29891025"></a>Alqahtani Z, Jamali F. Clinical outcomes of aspirin interaction with other non-steroidal anti-inflammatory drugs: a systematic review. <i>J Pharm Pharm Sci</i>. 2018;21(1s):29854. doi:10.18433/jpps29854<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/29891025/pubmed" id="29891025" target="_blank">29891025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35576364">
<a name="35576364"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG committee on clinical practice guidelines–obstetrics. Headaches in pregnancy and postpartum: ACOG clinical practice guideline no. 3. <i>Obstet Gynecol</i>. 2022;139(5):944-972. doi:10.1097/AOG.0000000000004766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/35576364/pubmed" id="35576364" target="_blank">35576364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30801474">
<a name="30801474"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 209: Obstetric analgesia and anesthesia.<i> Obstet Gynecol</i>. 2019;133(3):e208-e225. doi:10.1097/AOG.0000000000003132<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/30801474/pubmed" id="30801474" target="_blank">30801474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31376180">
<a name="31376180"></a>Ammar H, Ben Fredj N, Ben Fadhel N, et al. Celecoxib-induced bullous fixed drug eruption: an unusual presentation. <i>Br J Clin Pharmacol</i>. 2019;85(11):2638-2639. doi:10.1111/bcp.14072<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/31376180/pubmed" id="31376180" target="_blank">31376180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777151">
<a name="24777151"></a>Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. <i>Am J Gastroenterol</i>. 2014;109(6):811-819. doi:10.1038/ajg.2014.82<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/24777151/pubmed" id="24777151" target="_blank">24777151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17241570">
<a name="17241570"></a>Atzori L, Pinna AL, Pau M, Aste N, Zucca M, Ferreli C. Adverse cutaneous reactions to selective cyclooxygenase 2 inhibitors: experience of an Italian drug-surveillance center. <i>J Cutan Med Surg</i>. 2006;10(1):31-35. doi:10.1007/7140.2006.00012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/17241570/pubmed" id="17241570" target="_blank">17241570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32479922">
<a name="32479922"></a>Baker M, Perazella MA. NSAIDs in CKD: are they safe? <i>Am J Kidney Dis</i>. 2020;76(4):546-557. doi:10.1053/j.ajkd.2020.03.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/32479922/pubmed" id="32479922" target="_blank">32479922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15668365">
<a name="15668365"></a>Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. <i>Arch Intern Med</i>. 2005;165(2):189-192. doi:10.1001/archinte.165.2.189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/15668365/pubmed" id="15668365" target="_blank">15668365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Becker.2020">
<a name="Becker.2020"></a>Becker MA. Treatment of gout flares. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 14, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12222558">
<a name="12222558"></a>Berger P, Dwyer D, Corallo CE. Toxic epidermal necrolysis after celecoxib therapy. <i>Pharmacotherapy</i>. 2002;22(9):1193-1195. doi:10.1592/phco.22.13.1193.33513<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/12222558/pubmed" id="12222558" target="_blank">12222558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24663106">
<a name="24663106"></a>Bermas BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. <i>Curr Opin Rheumatol</i>. 2014;26(3):334-340.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/24663106/pubmed" id="24663106" target="_blank">24663106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23726390">
<a name="23726390"></a>Bhala N, Emberson J, Merhi A, et al; Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. <i>Lancet</i>. 2013;382(9894):769-779. doi:10.1016/S0140-6736(13)60900-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/23726390/pubmed" id="23726390" target="_blank">23726390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682313">
<a name="24682313"></a>Bhangu A, Singh P, Fitzgerald JE, Slesser A, Tekkis P. Postoperative nonsteroidal anti-inflammatory drugs and risk of anastomotic leak: meta-analysis of clinical and experimental studies. <i>World J Surg</i>. 2014;38(9):2247-2257. doi:10.1007/s00268-014-2531-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/24682313/pubmed" id="24682313" target="_blank">24682313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19017521">
<a name="19017521"></a>Bhatt DL, Scheiman J, Abraham NS, et al; American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.<i> J Am Coll Cardiol</i>. 2008;52(18):1502-1517. doi:10.1016/j.jacc.2008.08.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/19017521/pubmed" id="19017521" target="_blank">19017521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21705120">
<a name="21705120"></a>Bhave G, Neilson EG. Volume depletion versus dehydration: how understanding the difference can guide therapy. <i>Am J Kidney Dis</i>. 2011;58(2):302-309. doi:10.1053/j.ajkd.2011.02.395<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/21705120/pubmed" id="21705120" target="_blank">21705120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33942342">
<a name="33942342"></a>Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2021;74(2):1014-1048. doi:10.1002/hep.31884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/33942342/pubmed" id="33942342" target="_blank">33942342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23558845">
<a name="23558845"></a>Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. <i>Anesth Analg</i>. 2013;116(5):1063-1075.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/23558845/pubmed" id="23558845" target="_blank">23558845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Blumberg.2020">
<a name="Blumberg.2020"></a>Blumberg M. Anaphylactic reaction to celecoxib with elevated serum tryptase and positive drug skin test. <i>Ann Allergy Asthma Immunol</i>. 2020;125(suppl):S54.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11087881">
<a name="11087881"></a>Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. <i>N Engl J Med</i>. 2000;343(21):1520-1528. doi:10.1056/NEJM200011233432103<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/11087881/pubmed" id="11087881" target="_blank">11087881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15303450">
<a name="15303450"></a>Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. <i>Pharmacotherapy</i>. 2004;24(7):856-870.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/15303450/pubmed" id="15303450" target="_blank">15303450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12512867">
<a name="12512867"></a>Brix AE. Renal papillary necrosis. <i>Toxicol Pathol</i>. 2002;30(6):672-674. doi:10.1080/01926230290166760<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/12512867/pubmed" id="12512867" target="_blank">12512867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23453549">
<a name="23453549"></a>Brophy PD. Changing the paradigm in pediatric acute kidney injury. <i>J Pediatr</i>. 2013;162(6):1094-1096. doi:10.1016/j.jpeds.2013.01.065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/23453549/pubmed" id="23453549" target="_blank">23453549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23026982">
<a name="23026982"></a>Burbach GJ, Vajkoczy P, Zuberbier T. Celecoxib desensitization: continued temozolomide/celecoxib chemotherapy after a celecoxib-induced hypersensitivity reaction. <i>Anticancer Drugs</i>. 2012;23(10):1118-1120. doi:10.1097/CAD.0b013e32835824fa<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/23026982/pubmed" id="23026982" target="_blank">23026982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15037526">
<a name="15037526"></a>Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. <i>Circulation</i>. 2004;109(12):1468-1471. doi:10.1161/01.CIR.0000124715.27937.78<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/15037526/pubmed" id="15037526" target="_blank">15037526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11509629">
<a name="11509629"></a>Caughey GE, Cleland LG, Penglis PS, Gamble JR, James MJ. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. <i>J Immunol</i>. 2001;167(5):2831-2838. doi:10.4049/jimmunol.167.5.2831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/11509629/pubmed" id="11509629" target="_blank">11509629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Celebrex.1">
<a name="Celebrex.1"></a>Celebrex (celecoxib) [prescribing information]. New York, NY: Pfizer Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Celebrex.3">
<a name="Celebrex.3"></a>Celebrex (celecoxib) [prescribing information]. Morgantown, WV: Viatris Specialty LLC; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Celebrex.2">
<a name="Celebrex.2"></a>Celebrex (celecoxib) [product monograph]. Kirkland, Quebec, Canada: Upjohn Canada ULC; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17040369">
<a name="17040369"></a>Ch'ng A, Lowe M. Celecoxib allergies and cross-reactivity. <i>Intern Med J</i>. 2006;36(11):754-755. doi:10.1111/j.1445-5994.2006.01184.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/17040369/pubmed" id="17040369" target="_blank">17040369</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19299321">
<a name="19299321"></a>Chamberlin KW, Silverman AR. Celecoxib-associated anaphylaxis. <i>Ann Pharmacother</i>. 2009;43(4):777-781. doi:10.1345/aph.1L593<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/19299321/pubmed" id="19299321" target="_blank">19299321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16518289">
<a name="16518289"></a>Chamouard P, Walter P, Baumann R, Poupon R. Prolonged cholestasis associated with short-term use of celecoxib. <i>Gastroenterol Clin Biol</i>. 2005;29(12):1286-1288. doi:10.1016/s0399-8320(05)82223-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/16518289/pubmed" id="16518289" target="_blank">16518289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15840730">
<a name="15840730"></a>Chan AL. Celecoxib-induced deep-vein thrombosis. <i>Ann Pharmacother</i>. 2005;39(6):1138. doi:10.1345/aph.1E603<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/15840730/pubmed" id="15840730" target="_blank">15840730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16534006">
<a name="16534006"></a>Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. <i>Circulation</i>. 2006;113(12):1578-1587. doi:10.1161/CIRCULATIONAHA.105.595793<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/16534006/pubmed" id="16534006" target="_blank">16534006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30345832">
<a name="30345832"></a>Chan CW, Yap YN. Pharmacotherapeutic management of gout in patients with cardiac disease [published online October 20, 2018]. <i>Expert Opin Pharmacother</i>. doi:10.1080/14656566.2018.1536747<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/30345832/pubmed" id="30345832" target="_blank">30345832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20638563">
<a name="20638563"></a>Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. <i>Lancet</i>. 2010;376(9736):173-179. doi:10.1016/S0140-6736(10)60673-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/20638563/pubmed" id="20638563" target="_blank">20638563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11964481">
<a name="11964481"></a>Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. <i>Science</i>. 2002;296(5567):539-541. doi:10.1126/science.1068711<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/11964481/pubmed" id="11964481" target="_blank">11964481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26945352">
<a name="26945352"></a>Chou CI, Shih CJ, Chen YT, et al. Adverse effects of oral nonselective and cyclooxygenase-2-selective NSAIDs on hospitalization for acute kidney injury: a nested case-control cohort study. <i>Medicine (Baltimore)</i>. 2016;95(9):e2645. doi:10.1097/MD.0000000000002645<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/26945352/pubmed" id="26945352" target="_blank">26945352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26827847">
<a name="26827847"></a>Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. <i>J Pain</i>. 2016;17(2):131-157. doi:10.1016/j.jpain.2015.12.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/26827847/pubmed" id="26827847" target="_blank">26827847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19940308">
<a name="19940308"></a>Cimbollek S, Quiralte J, Avila R. COX-2 inhibitors in patients with sensitivity to nonselective NSAIDs. <i>N Engl J Med</i>. 2009;361(22):2197-2198. doi:10.1056/NEJMc0907208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/19940308/pubmed" id="19940308" target="_blank">19940308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6363936">
<a name="6363936"></a>Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. <i>N Engl J Med</i>. 1984;310(9):563-572. doi:10.1056/NEJM198403013100905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/6363936/pubmed" id="6363936" target="_blank">6363936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9626023">
<a name="9626023"></a>Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. <i>Am J Med</i>. 1998;104(5):413-421. doi:10.1016/s0002-9343(98)00091-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/9626023/pubmed" id="9626023" target="_blank">9626023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19695387">
<a name="19695387"></a>Daniels S, Robbins J, West CR, Nemeth MA. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies. <i>Clin Ther</i>. 2009;31(6):1192-1208. doi:10.1016/j.clinthera.2009.06.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/19695387/pubmed" id="19695387" target="_blank">19695387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31273431">
<a name="31273431"></a>Dathe K, Hultzsch S, Pritchard LW, Schaefer C. Risk estimation of fetal adverse effects after short-term second trimester exposure to non-steroidal anti-inflammatory drugs: a literature review. <i>Eur J Clin Pharmacol</i>. 2019;75(10):1347-1353. doi:10.1007/s00228-019-02712-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/31273431/pubmed" id="31273431" target="_blank">31273431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10749518">
<a name="10749518"></a>Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. <i>Clin Pharmacokinet</i>. 2000;38(3):225-242. doi:10.2165/00003088-200038030-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/10749518/pubmed" id="10749518" target="_blank">10749518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29799625">
<a name="29799625"></a>Delzer LM, Golightly LK, Kiser TH, Biggins SW, Lewis VJ, Kim II. Calcineurin inhibitor and nonsteroidal anti-inflammatory drug interaction: implications of changes in renal function associated with concurrent use. <i>J Clin Pharmacol</i>. 2018;58(11):1443-1451. doi:10.1002/jcph.1264<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/29799625/pubmed" id="29799625" target="_blank">29799625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12162474">
<a name="12162474"></a>Doyle G, Jayawardena S, Ashraf E, et al. Efficacy and Tolerability of Nonprescription Ibuprofen Versus Celecoxib for Dental Pain. <i>J Clin Pharmacol</i>. 2002;42(8):912-919.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/12162474/pubmed" id="12162474" target="_blank">12162474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15583611">
<a name="15583611"></a>Drago F, Brusati C, Desirello G, Cacciapuoti M, Rebora A. Cutaneous vasculitis induced by cyclo-oxygenase-2 selective inhibitors. <i>J Am Acad Dermatol</i>. 2004;51(6):1029-1030. doi:10.1016/j.jaad.2004.08.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/15583611/pubmed" id="15583611" target="_blank">15583611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19701976">
<a name="19701976"></a>El Hajj II, Malik SM, Alwakeel HR, Shaikh OS, Sasatomi E, Kandil HM. Celecoxib-induced cholestatic liver failure requiring orthotopic liver transplantation. <i>World J Gastroenterol</i>. 2009;15(31):3937-3939. doi:10.3748/wjg.15.3937<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/19701976/pubmed" id="19701976" target="_blank">19701976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Elyxyb.1">
<a name="Elyxyb.1"></a>Elyxyb (celecoxib) [prescribing information]. Raleigh, NC: Biodelivery Sciences International Inc; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10609815">
<a name="10609815"></a>Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. <i>Lancet</i>. 1999;354(9196):2106-2111. doi:10.1016/S0140-6736(99)02332-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/10609815/pubmed" id="10609815" target="_blank">10609815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12013363">
<a name="12013363"></a>Ernst EJ, Egge JA. Celecoxib-induced erythema multiforme with glyburide cross-reactivity. <i>Pharmacotherapy</i>. 2002;22(5):637-640. doi:10.1592/phco.22.8.637.33200<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/12013363/pubmed" id="12013363" target="_blank">12013363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2015">
<a name="FDA.2015"></a>FDA drug safety communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. Food and Drug Administration. Updated July 9, 2015. Accessed April 29, 2022. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17156357">
<a name="17156357"></a>Figueroa J, Ortega N, Almeida L, Blanco C, Castillo R. Sulfonamide allergy without cross-reactivity to celecoxib. <i>Allergy</i>. 2007;62(1):93. doi:10.1111/j.1398-9995.2006.01270.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/17156357/pubmed" id="17156357" target="_blank">17156357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11793622">
<a name="11793622"></a>Fisher AA, Le Couteur DG. Intracerebral hemorrhage following possible interaction between celecoxib and clopidogrel. <i>Ann Pharmacother</i>. 2001;35(12):1567-1569. doi:10.1345/aph.1A110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/11793622/pubmed" id="11793622" target="_blank">11793622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12425513">
<a name="12425513"></a>Friedman B, Orlet HK, Still JM, Law E. Toxic epidermal necrolysis due to administration of celecoxib (Celebrex). <i>South Med J</i>. 2002;95(10):1213-1214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/12425513/pubmed" id="12425513" target="_blank">12425513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gaffo.1">
<a name="Gaffo.1"></a>Gaffo AL. Treatment of gout flares. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12789245">
<a name="12789245"></a>Gagnon R, Julien M, Gold P. Selective celecoxib-associated anaphylactoid reaction. <i>J Allergy Clin Immunol</i>. 2003;111(6):1404-1405. doi:10.1067/mai.2003.1465<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/12789245/pubmed" id="12789245" target="_blank">12789245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16390357">
<a name="16390357"></a>Gardiner SJ, Doogue MP, Zhang M, et al. Quantification of Infant Exposure to Celecoxib Through Breast Milk. <i>Br J Clin Pharmacol</i>. 2006;61(1):101-104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/16390357/pubmed" id="16390357" target="_blank">16390357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25247621">
<a name="25247621"></a>Garratty G, Arndt PA. Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007. <i>Immunohematology</i>. 2014;30(2):66-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/25247621/pubmed" id="25247621" target="_blank">25247621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Geis.1">
<a name="Geis.1"></a>Geis GS, et al. Efficacy and Safety of Celecoxib, A Specific COX-2 Inhibitor, in Patients With Rheumatoid Arthritis. <i>Arthritis Rheum</i>. 1998;41(9)(suppl):316:1699.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19171810">
<a name="19171810"></a>Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. <i>Arch Intern Med</i>. 2009;169(2):141-149. doi:10.1001/archinternmed.2008.525<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/19171810/pubmed" id="19171810" target="_blank">19171810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18359332">
<a name="18359332"></a>Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R, Ruijne N. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. <i>Am J Cardiol</i>. 2008;101(7):1060-1063. doi:10.1016/j.amjcard.2007.11.054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/18359332/pubmed" id="18359332" target="_blank">18359332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15237269">
<a name="15237269"></a>Goeschke B, Braathen LR. Acute generalized exanthematic pustulosis: a case and an overview of side effects affecting the skin caused by celecoxib and other COX-2 inhibitors reported so far. <i>Dermatology</i>. 2004;209(1):53-56. doi:10.1159/000078588<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/15237269/pubmed" id="15237269" target="_blank">15237269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24661957">
<a name="24661957"></a>Gómez de la Fuente E, Pampín Franco A, Caro Gutiérrez D, López Estebaranz JL. Fixed drug eruption due to etoricoxib in a patient with tolerance to celecoxib: the value of patch testing. <i>Actas Dermosifiliogr</i>. 2014;105(3):314-315. doi:10.1016/j.adengl.2013.04.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/24661957/pubmed" id="24661957" target="_blank">24661957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17349452">
<a name="17349452"></a>Gooch K, Culleton BF, Manns BJ, et al. NSAID use and progression of chronic kidney disease. <i>Am J Med</i>. 2007;120(3):280.e1-280.e2807. doi:10.1016/j.amjmed.2006.02.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/17349452/pubmed" id="17349452" target="_blank">17349452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15705456">
<a name="15705456"></a>Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. <i>Lancet</i>. 2005;365(9458):475-481. doi:10.1016/S0140-6736(05)17864-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/15705456/pubmed" id="15705456" target="_blank">15705456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11146365">
<a name="11146365"></a>Grob M, Scheidegger P, Wüthrich B. Allergic skin reaction to celecoxib. <i>Dermatology</i>. 2000;201(4):383. doi:10.1159/000051569<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/11146365/pubmed" id="11146365" target="_blank">11146365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18541831">
<a name="18541831"></a>Haag MD, Bos MJ, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. <i>Arch Intern Med</i>. 2008;168(11):1219-1224. doi:10.1001/archinte.168.11.1219<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/18541831/pubmed" id="18541831" target="_blank">18541831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15479658">
<a name="15479658"></a>Hale TW, McDonald R, Boger J. Transfer of Celecoxib Into Human Milk. <i>J Hum Lact</i>. 2004;20(4):397-403.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/15479658/pubmed" id="15479658" target="_blank">15479658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12556663">
<a name="12556663"></a>Handler J. Drug-induced hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2003;5(1):83-85. doi:10.1111/j.1524-6175.2003.01923.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/12556663/pubmed" id="12556663" target="_blank">12556663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12046048">
<a name="12046048"></a>Henao J, Hisamuddin I, Nzerue CM, Vasandani G, Hewan-Lowe K. Celecoxib-induced acute interstitial nephritis. <i>Am J Kidney Dis</i>. 2002;39(6):1313-1317. doi:10.1053/ajkd.2002.33412<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/12046048/pubmed" id="12046048" target="_blank">12046048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15947398">
<a name="15947398"></a>Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. <i>BMJ</i>. 2005;330(7504):1366. doi:10.1136/bmj.330.7504.1366<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/15947398/pubmed" id="15947398" target="_blank">15947398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18193919">
<a name="18193919"></a>Hong Y, Gengo FM, Rainka MM, Bates VE, Mager DE. Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects. <i>Clin Pharmacokinet</i>. 2008;47(2):129-137. doi:10.2165/00003088-200847020-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/18193919/pubmed" id="18193919" target="_blank">18193919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30317488">
<a name="30317488"></a>Horsley RD, Vogels ED, McField DAP, et al. Multimodal postoperative pain control is effective and reduces opioid use after laparoscopic Roux-en-Y gastric bypass. <i>Obes Surg</i>. 2019;29(2):394-400. doi:10.1007/s11695-018-3526-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/30317488/pubmed" id="30317488" target="_blank">30317488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15754275">
<a name="15754275"></a>Huerta C, Castellsague J, Varas-Lorenzo C, García Rodríguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. <i>Am J Kidney Dis</i>. 2005;45(3):531-539. doi:10.1053/j.ajkd.2004.12.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/15754275/pubmed" id="15754275" target="_blank">15754275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15644481">
<a name="15644481"></a>Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? [published correction appears in Ann Pharmacother. 2005;39(7-8):1373]. A<i>nn Pharmacother</i>. 2005;39(2):290-301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/15644481/pubmed" id="15644481" target="_blank">15644481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27853386">
<a name="27853386"></a>Kaewput W, Disorn P, Satirapoj B. Selective cyclooxygenase-2 inhibitor use and progression of renal function in patients with chronic kidney disease: a single-center retrospective cohort study. <i>Int J Nephrol Renovasc Dis</i>. 2016;9:273-278. doi:10.2147/IJNRD.S121698<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/27853386/pubmed" id="27853386" target="_blank">27853386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9485090">
<a name="9485090"></a>Karim A, et al. Celecoxib, a Specific COX-2 Inhibitor, Lacks Significant Drug-Drug Interactions With Methotrexate or Warfarin. <i>Arthritis Rheum</i>. 1998;41(9)(suppl):315:1698.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/9485090/pubmed" id="9485090" target="_blank">9485090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2724096">
<a name="2724096"></a>Kean WF, Lock CJ, Rischke J, Butt R, Buchanan WW, Howard-Lock H. Effect of R and S enantiomers of naproxen on aggregation and thromboxane production in human platelets. <i>J Pharm Sci</i>. 1989;78(4):324-327. doi:10.1002/jps.2600780413<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/2724096/pubmed" id="2724096" target="_blank">2724096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31495421">
<a name="31495421"></a>Khan DA, Knowles SR, Shear NH. Sulfonamide hypersensitivity: fact and fiction. <i>J Allergy Clin Immunol Pract</i>. 2019;7(7):2116-2123. doi:10.1016/j.jaip.2019.05.034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/31495421/pubmed" id="31495421" target="_blank">31495421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.2">
<a name="KDIGO.2"></a>Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. <i>Kidney Int Suppl (2013)</i>. 2013;3(1):1-150. https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guidelines for the evaluation and management of chronic kidney disease. <i>Kidney Inter, Suppl.</i> 2013;3:1-150.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24587953">
<a name="24587953"></a>Kim YJ, Lim KH, Kim MY, et al. Cross-reactivity to acetaminophen and celecoxib according to the type of nonsteroidal anti-inflammatory drug hypersensitivity. <i>Allergy Asthma Immunol Res</i>. 2014;6(2):156-162. doi:10.4168/aair.2014.6.2.156<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/24587953/pubmed" id="24587953" target="_blank">24587953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11961179">
<a name="11961179"></a>Knijff-Dutmer EA, Kalsbeek-Batenburg EM, Koerts J, van de Laar MA. Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis. <i>Rheumatology (Oxford)</i>. 2002;41(4):458-461. doi:10.1093/rheumatology/41.4.458<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/11961179/pubmed" id="11961179" target="_blank">11961179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12523466">
<a name="12523466"></a>Knoppert DC, Stempak D, Baruchel S, et al. Celecoxib in Human Milk: A Case Report. <i>Pharmacotherapy</i>. 2003;23(1):97-100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/12523466/pubmed" id="12523466" target="_blank">12523466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11330653">
<a name="11330653"></a>Knowles S, Shapiro L, Shear NH. Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of 'sulfa' allergy. <i>Drug Saf</i>. 2001;24(4):239-247. doi:10.2165/00002018-200124040-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/11330653/pubmed" id="11330653" target="_blank">11330653</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24280110">
<a name="24280110"></a>Kohli P, Steg PG, Cannon CP, et al. NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. <i>Am J Med</i>. 2014;127(1):53-60.e1. doi:10.1016/j.amjmed.2013.08.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/24280110/pubmed" id="24280110" target="_blank">24280110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27881247">
<a name="27881247"></a>Koncicki HM, Unruh M, Schell JO. Pain management in CKD: a guide for nephrology providers. <i>Am J Kidney Dis</i>. 2017;69(3):451-460. doi:10.1053/j.ajkd.2016.08.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/27881247/pubmed" id="27881247" target="_blank">27881247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21631520">
<a name="21631520"></a>Kowalski ML, Makowska JS, Blanca M, et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. <i>Allergy</i>. 2011;66(7):818-829. doi:10.1111/j.1398-9995.2011.02557.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/21631520/pubmed" id="21631520" target="_blank">21631520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21878579">
<a name="21878579"></a>Krishnaswami S, Hutmacher MM, Robbins JL, et al. Dosing celecoxib in pediatric patients with juvenile rheumatoid arthritis.<i> J Clin Pharmacol.</i> 2012;52(8):1134-1149. doi:10.1177/0091270011412184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/21878579/pubmed" id="21878579" target="_blank">21878579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12900801">
<a name="12900801"></a>Kurella M, Bennett WM, Chertow GM. Analgesia in patients with ESRD: a review of available evidence. <i>Am J Kidney Dis</i>. 2003;42(2):217-228. doi:10.1016/s0272-6386(03)00645-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/12900801/pubmed" id="12900801" target="_blank">12900801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16180941">
<a name="16180941"></a>La Grenade L, Lee L, Weaver J, et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. <i>Drug Saf</i>. 2005;28(10):917-924. doi:10.2165/00002018-200528100-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/16180941/pubmed" id="16180941" target="_blank">16180941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12014386">
<a name="12014386"></a>Lago P, Bettiol T, Salvadori S, et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. <i>Eur J Pediatr</i>. 2002;161(4):202-207. doi:10.1007/s00431-002-0915-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/12014386/pubmed" id="12014386" target="_blank">12014386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20955443">
<a name="20955443"></a>Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. <i>Aliment Pharmacol Ther</i>. 2010;32(10):1240-1248. doi:10.1111/j.1365-2036.2010.04465.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/20955443/pubmed" id="20955443" target="_blank">20955443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9002006">
<a name="9002006"></a>Lane NE. Pain Management in Osteoarthritis: The Role of COX-2 Inhibitors. <i>J Rheumatol</i>. 1997;24(suppl 49):20-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/9002006/pubmed" id="9002006" target="_blank">9002006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23299844">
<a name="23299844"></a>Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. <i>BMJ</i>. 2013;346:e8525. doi:10.1136/bmj.e8525<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/23299844/pubmed" id="23299844" target="_blank">23299844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30449626">
<a name="30449626"></a>Larrey E, Patouraux S, Spreux A, et al. Fatal cholestatic hepatitis after a single dose of celecoxib. <i>Clin Res Hepatol Gastroenterol</i>. 2019;43(5):e82-e85. doi:10.1016/j.clinre.2018.10.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/30449626/pubmed" id="30449626" target="_blank">30449626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20582911">
<a name="20582911"></a>Lee CH, Wang JD, Chen PC. Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs. <i>Pharmacoepidemiol Drug Saf</i>. 2010;19(7):708-714. doi:10.1002/pds.1966<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/20582911/pubmed" id="20582911" target="_blank">20582911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18583892">
<a name="18583892"></a>Lee JH, Park HK, Heo J, et al. Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome induced by celecoxib and anti-tuberculosis drugs. <i>J Korean Med Sci</i>. 2008;23(3):521-525. doi:10.3346/jkms.2008.23.3.521<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/18583892/pubmed" id="18583892" target="_blank">18583892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26488335">
<a name="26488335"></a>Lee SK, Lee DY, Kim DJ, Kim MS, Lee UH, Hahm JH. Acute generalized exanthematous pustulosis induced by celecoxib. <i>J Cutan Pathol</i>. 2016;43(1):80-81. doi:10.1111/cup.12604<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/26488335/pubmed" id="26488335" target="_blank">26488335</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10664917">
<a name="10664917"></a>Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. <i>J Clin Pharmacol</i>. 2000;40(2):124-132. doi:10.1177/00912700022008766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/10664917/pubmed" id="10664917" target="_blank">10664917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11476468">
<a name="11476468"></a>Levy MB, Fink JN. Anaphylaxis to celecoxib. <i>Ann Allergy Asthma Immunol</i>. 2001;87(1):72-73. doi:10.1016/S1081-1206(10)62327-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/11476468/pubmed" id="11476468" target="_blank">11476468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31100553">
<a name="31100553"></a>Li L, Laidlaw T. Cross-reactivity and tolerability of celecoxib in adult patients with NSAID hypersensitivity. <i>J Allergy Clin Immunol Pract</i>. 2019;7(8):2891-2893.e4. doi:10.1016/j.jaip.2019.04.042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/31100553/pubmed" id="31100553" target="_blank">31100553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9002004">
<a name="9002004"></a>Lipsky PE, Isakson PC. Outcome of Specific COX-2 Inhibition in Rheumatoid Arthritis. <i>J Rheumatol</i>. 1997;24(suppl 49):9-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/9002004/pubmed" id="9002004" target="_blank">9002004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33658842">
<a name="33658842"></a>Lipton RB, Munjal S, Dodick DW, Tepper SJ, Serrano D, Iaconangelo C. Acute treatment of migraine with celecoxib oral solution: results of a randomized, placebo-controlled clinical trial. <i>J Pain Res</i>. 2021;14:549-560. doi:10.2147/JPR.S287571<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/33658842/pubmed" id="33658842" target="_blank">33658842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26224322">
<a name="26224322"></a>Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. <i>Cochrane Database Syst Rev</i>. 2015;2015(7):CD001751. doi:10.1002/14651858.CD001751.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/26224322/pubmed" id="26224322" target="_blank">26224322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29595994">
<a name="29595994"></a>Martin E, Vickers B, Landau R, Reece-Stremtan S. ABM clinical protocol #28, peripartum analgesia and anesthesia for the breastfeeding mother. <i>Breastfeed Med</i>. 2018;13(3):164-171. doi:10.1089/bfm.2018.29087.ejm<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/29595994/pubmed" id="29595994" target="_blank">29595994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Mengle-Gaw L, et al. A Study of the Platelet Effects of SC-58635, A Novel COX-2 Selective Inhibitor. <i>Arthritis Rheum</i>. 1998;41(9)(suppl):93-374.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31416889">
<a name="31416889"></a>Mérida E, Praga M. NSAIDs and nephrotic syndrome. <i>Clin J Am Soc Nephrol</i>. 2019;14(9):1280-1282. doi:10.2215/CJN.08090719<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/31416889/pubmed" id="31416889" target="_blank">31416889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31215658">
<a name="31215658"></a>Miroux-Catarino A, Silva L, Amaro C, Ferreira ML, Viana I. Bullous fixed drug eruption induced by etoricoxib, confirmed by patch testing, with tolerance to celecoxib. <i>Contact Dermatitis</i>. 2019;81(5):388-389. doi:10.1111/cod.13339<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/31215658/pubmed" id="31215658" target="_blank">31215658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23360563">
<a name="23360563"></a>Misurac JM, Knoderer CA, Leiser JD, Nailescu C, Wilson AC, Andreoli SP. Nonsteroidal anti-inflammatory drugs are an important cause of acute kidney injury in children. <i>J Pediatr</i>. 2013;162(6):1153-1159.e1. doi:10.1016/j.jpeds.2012.11.069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/23360563/pubmed" id="23360563" target="_blank">23360563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10879670">
<a name="10879670"></a>Mohammed EP, Stevens JM. Recurrence of Arthrotec-associated nephrotic syndrome with re-challenge. <i>Clin Nephrol</i>. 2000;53(6):483-485.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/10879670/pubmed" id="10879670" target="_blank">10879670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11315375">
<a name="11315375"></a>Moore PA, Hersh EV. Celecoxib and Rofecoxib. The Role of COX-2 Inhibitors in Dental Practice. <i>J Am Dent Assoc</i>. 2001;132(4):451-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/11315375/pubmed" id="11315375" target="_blank">11315375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24388008">
<a name="24388008"></a>Morales DR, Lipworth BJ, Guthrie B, Jackson C, Donnan PT, Santiago VH. Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: meta-analysis of controlled clinical trials. <i>J Allergy Clin Immunol</i>. 2014;134(1):40-45. doi:10.1016/j.jaci.2013.10.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/24388008/pubmed" id="24388008" target="_blank">24388008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28795997">
<a name="28795997"></a>Mukthinuthalapati PK, Fontana RJ, Vuppalanchi R, Chalasani N, Ghabril M. Celecoxib-induced liver injury: analysis of published case reports and cases reported to the Food and Drug Administration. <i>J Clin Gastroenterol</i>. 2018;52(2):114-122. doi:10.1097/MCG.0000000000000888<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/28795997/pubmed" id="28795997" target="_blank">28795997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11470953">
<a name="11470953"></a>Nachimuthu S, Volfinzon L, Gopal L. Acute hepatocellular and cholestatic injury in a patient taking celecoxib. <i>Postgrad Med J</i>. 2001;77(910):548-550. doi:10.1136/pmj.77.910.548<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/11470953/pubmed" id="11470953" target="_blank">11470953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31264694">
<a name="31264694"></a>Nash DM, Markle-Reid M, Brimble KS, et al. Nonsteroidal anti-inflammatory drug use and risk of acute kidney injury and hyperkalemia in older adults: a population-based study. <i>Nephrol Dial Transplant</i>. 2019;34(7):1145-1154. doi:10.1093/ndt/gfz062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/31264694/pubmed" id="31264694" target="_blank">31264694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. Published September 3, 2014. Accessed April 29, 2022. https://www.nice.org.uk/guidance/cg183
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9002003">
<a name="9002003"></a>Needleman P, Isakson PC. The Discovery and Function of COX-2. <i>J Rheumatol</i>. 1997;24(suppl 49):6-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/9002003/pubmed" id="9002003" target="_blank">9002003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27959716">
<a name="27959716"></a>Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. <i>N Engl J Med</i>. 2016;375(26):2519-2529. doi:10.1056/NEJMoa1611593<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/27959716/pubmed" id="27959716" target="_blank">27959716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15713945">
<a name="15713945"></a>Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib After Cardiac Surgery. <i>N Engl J Med</i>. 2005;352(11):1081-1091.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/15713945/pubmed" id="15713945" target="_blank">15713945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3045551">
<a name="3045551"></a>Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ 2nd. Clinical implications of prostaglandin and thromboxane A2 formation (2). <i>N Engl J Med</i>. 1988;319(12):761-767. doi:10.1056/NEJM198809223191206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/3045551/pubmed" id="3045551" target="_blank">3045551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23633310">
<a name="23633310"></a>Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. <i>Cochrane Database Syst Rev</i>. 2013;(4):CD003481. doi:10.1002/14651858.CD003481.pub5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/23633310/pubmed" id="23633310" target="_blank">23633310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28052268">
<a name="28052268"></a>Otani K, Tanigawa T, Watanabe T, et al. Microbiota plays a key role in non-steroidal anti-inflammatory drug-induced small intestinal damage. <i>Digestion</i>. 2017;95(1):22-28. doi:10.1159/000452356<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/28052268/pubmed" id="28052268" target="_blank">28052268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28748412">
<a name="28748412"></a>Pal A, Shenoy S, Gautam A, et al. Pharmacokinetics of DFN-15, a novel oral solution of celecoxib, versus celecoxib 400-mg capsules: a randomized crossover study in fasting healthy volunteers. <i>Clin Drug Investig</i>. 2017;37(10):937-946. doi:10.1007/s40261-017-0548-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/28748412/pubmed" id="28748412" target="_blank">28748412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14742817">
<a name="14742817"></a>Papaioannides DH, Korantzopoulos PG, Giotis CH. Aseptic meningitis possibly associated with celecoxib. <i>Ann Pharmacother</i>. 2004;38(1):172. doi:10.1345/aph.1D238<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/14742817/pubmed" id="14742817" target="_blank">14742817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16469671">
<a name="16469671"></a>Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of <i>Helicobacter pylori</i> and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. <i>Clin Gastroenterol Hepatol</i>. 2006;4(2):130-142. doi:10.1016/j.cgh.2005.10.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/16469671/pubmed" id="16469671" target="_blank">16469671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14996398">
<a name="14996398"></a>Perna AG, Woodruff CA, Markus RF, Hsu S. Toxic epidermal necrolysis as a complication of treatment with celecoxib. <i>Dermatol Online J</i>. 2003;9(5):25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/14996398/pubmed" id="14996398" target="_blank">14996398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2012355">
<a name="2012355"></a>Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. <i>Ann Intern Med</i>. 1991;114(9):735-740. doi:10.7326/0003-4819-114-9-735<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/2012355/pubmed" id="2012355" target="_blank">2012355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Portenoy.1">
<a name="Portenoy.1"></a>Portenoy RK, Ahmed E, Keilson YY. Cancer pain management: Use of acetaminophen and nonsteroidal anti-inflammatory drugs. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 29, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25439535">
<a name="25439535"></a>Rahman S, Malcoun A. Nonsteroidal antiinflammatory drugs, cyclooxygenase-2, and the kidneys. <i>Prim Care</i>. 2014;41(4):803-821. doi:10.1016/j.pop.2014.09.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/25439535/pubmed" id="25439535" target="_blank">25439535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20031832">
<a name="20031832"></a>Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. <i>Circ Cardiovasc Qual Outcomes</i>. 2009;2(3):155-163. doi:10.1161/CIRCOUTCOMES.108.805689<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/20031832/pubmed" id="20031832" target="_blank">20031832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29624435">
<a name="29624435"></a>Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2017. <i>Breastfeed Med</i>. 2017;12(9):500-506. doi:10.1089/bfm.2017.29054.srt<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/29624435/pubmed" id="29624435" target="_blank">29624435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling,</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25989969">
<a name="25989969"></a>Regis AC, Germann CA, Crowell JG. Myocardial infarction in the setting of anaphylaxis to celecoxib: a case of Kounis syndrome. <i>J Emerg Med</i>. 2015;49(2):e39-e43. doi:10.1016/j.jemermed.2015.02.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/25989969/pubmed" id="25989969" target="_blank">25989969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17556027">
<a name="17556027"></a>Rostom A, Muir K, Dubé C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. <i>Clin Gastroenterol Hepatol</i>. 2007;5(7):818-768. doi:10.1016/j.cgh.2007.03.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/17556027/pubmed" id="17556027" target="_blank">17556027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29020251">
<a name="29020251"></a>Ruschitzka F, Borer JS, Krum H, et al. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. <i>Eur Heart J</i>. 2017;38(44):3282-3292. doi:10.1093/eurheartj/ehx508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/29020251/pubmed" id="29020251" target="_blank">29020251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529‐556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22629288">
<a name="22629288"></a>Sands G, Shell B, Zhang R. Adverse events in patients with blood loss: a pooled analysis of 51 clinical studies from the celecoxib clinical trial database. <i>Open Rheumatol J</i>. 2012;6:44-49. doi:10.2174/1874312901206010044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/22629288/pubmed" id="22629288" target="_blank">22629288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19269020">
<a name="19269020"></a>Schjerning O, Larsen TB, Damkier P. The impact of selective and non-selective non-steroid anti-inflammatory drugs on secondary hemostasis in healthy volunteers. <i>Thromb Res</i>. 2009;124(2):208-212. doi:10.1016/j.thromres.2009.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/19269020/pubmed" id="19269020" target="_blank">19269020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24690187">
<a name="24690187"></a>Schjerning Olsen AM, Fosbøl EL, Gislason GH. The impact of NSAID treatment on cardiovascular risk - insight from Danish observational data. <i>Basic Clin Pharmacol Toxicol</i>. 2014;115(2):179-184. doi:10.1111/bcpt.12244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/24690187/pubmed" id="24690187" target="_blank">24690187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21555710">
<a name="21555710"></a>Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. <i>Circulation</i>. 2011;123(20):2226-2235. doi:10.1161/CIRCULATIONAHA.110.004671<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/21555710/pubmed" id="21555710" target="_blank">21555710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25710657">
<a name="25710657"></a>Schjerning Olsen AM, Gislason GH, McGettigan P, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. <i>JAMA</i>. 2015;313(8):805-814. doi:10.1001/jama.2015.0809<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/25710657/pubmed" id="25710657" target="_blank">25710657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26984863">
<a name="26984863"></a>Schmidt M, Lamberts M, Schjerning Olsen AM, et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>Eur Heart J</i>. 2016;37(13):1015-1023. doi:10.1093/eurheartj/ehv505<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/26984863/pubmed" id="26984863" target="_blank">26984863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11897288">
<a name="11897288"></a>Schneider F, Meziani F, Chartier C, Alt M, Jaeger A. Fatal allergic vasculitis associated with celecoxib. <i>Lancet</i>. 2002;359(9309):852-853. doi:10.1016/S0140-6736(02)07922-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/11897288/pubmed" id="11897288" target="_blank">11897288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17005625">
<a name="17005625"></a>Schneider V, Lévesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. <i>Am J Epidemiol</i>. 2006;164(9):881-889. doi:10.1093/aje/kwj331<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/17005625/pubmed" id="17005625" target="_blank">17005625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22859357">
<a name="22859357"></a>Schumacher HR, Berger MF, Li-Yu J, Perez-Ruiz F, Burgos-Vargas R, Li C. Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial. <i>J Rheumatol</i>. 2012;39(9):1859-1866. doi:10.3899/jrheum.110916<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/22859357/pubmed" id="22859357" target="_blank">22859357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14510732">
<a name="14510732"></a>Schuster C, Wüthrich B. Anaphylactic drug reaction to celecoxib and sulfamethoxazole: cross reactivity or coincidence? <i>Allergy</i>. 2003;58(10):1072. doi:10.1034/j.1398-9995.2003.00116.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/14510732/pubmed" id="14510732" target="_blank">14510732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schwedt.1">
<a name="Schwedt.1"></a>Schwedt TJ, Garza I. Acute treatment of migraine in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 10, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7306246">
<a name="7306246"></a>Shah GM, Muhalwas KK, Winer RL. Renal papillary necrosis due to ibuprofen. <i>Arthritis Rheum</i>. 1981;24(9):1208-1210. doi:10.1002/art.1780240917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/7306246/pubmed" id="7306246" target="_blank">7306246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12580647">
<a name="12580647"></a>Shapiro LE, Knowles SR, Weber E, Neuman MG, Shear NH. Safety of celecoxib in individuals allergic to sulfonamide: a pilot study. <i>Drug Saf</i>. 2003;26(3):187-195. doi:10.2165/00002018-200326030-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/12580647/pubmed" id="12580647" target="_blank">12580647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10979111">
<a name="10979111"></a>Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. <i>JAMA</i>. 2000;284(10):1247-1255. doi:10.1001/jama.284.10.1247<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/10979111/pubmed" id="10979111" target="_blank">10979111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9751091">
<a name="9751091"></a>Simon LS, et al. Preliminary Study of the Safety and Efficacy of SC-58635, a Novel Cyclo-oxygenase 2 Inhibitor: Efficacy and Safety in Two Placebo-Controlled Trials in Osteoarthritis and Rheumatoid Arthritis, and Studies of Gastrointestinal and Platelet Effects. <i>Arthritis Rheum</i>. 1998;41:1591-1602.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/9751091/pubmed" id="9751091" target="_blank">9751091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10580457">
<a name="10580457"></a>Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. <i>JAMA</i>. 1999;282(20):1921-1928. doi:10.1001/jama.282.20.1921<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/10580457/pubmed" id="10580457" target="_blank">10580457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16490472">
<a name="16490472"></a>Singh G, Fort JG, Goldstein JL, et al; SUCCESS-I investigators. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. <i>Am J Med</i>. 2006;119(3):255-266. doi:10.1016/j.amjmed.2005.09.054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/16490472/pubmed" id="16490472" target="_blank">16490472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23868909">
<a name="23868909"></a>Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. <i>Ann Rheum Dis</i>. 2014;73(2):328-335.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/23868909/pubmed" id="23868909" target="_blank">23868909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15242722">
<a name="15242722"></a>Slatore CG, Tilles SA. Sulfonamide hypersensitivity. <i>Immunol Allergy Clin North Am</i>. 2004;24(3):477-490.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/15242722/pubmed" id="15242722" target="_blank">15242722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28756267">
<a name="28756267"></a>Solomon DH, Husni ME, Libby PA, et al. The risk of major NSAID toxicity with celecoxib, ibuprofen, or naproxen: a secondary analysis of the PRECISION trial. <i>Am J Med</i>. 2017;130(12):1415-1422.e4. doi:10.1016/j.amjmed.2017.06.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/28756267/pubmed" id="28756267" target="_blank">28756267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15713944">
<a name="15713944"></a>Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention. <i>N Engl J Med</i>. 2005;352(11):1071-180.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/15713944/pubmed" id="15713944" target="_blank">15713944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19530981">
<a name="19530981"></a>Soni P, Shell B, Cawkwell G, Li C, Ma H. The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials. <i>Curr Med Res Opin</i>. 2009;25(8):1841-1851. doi:10.1185/03007990903018279<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/19530981/pubmed" id="19530981" target="_blank">19530981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29568654">
<a name="29568654"></a>Sriuttha P, Sirichanchuen B, Permsuwan U. Hepatotoxicity of nonsteroidal anti-inflammatory drugs: a systematic review of randomized controlled trials. <i>Int J Hepatol</i>. 2018;2018:5253623. doi:10.1155/2018/5253623<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/29568654/pubmed" id="29568654" target="_blank">29568654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16153401">
<a name="16153401"></a>Stempak D, Bukaveckas BL, Linder M, et al. Cytochrome P450 2C9 Genotype: Impact on Celecoxib Safety and Pharmacokinetics in a Pediatric Patient. <i>Clin Pharmacol Ther</i>. 2005;78(3):309-310.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/16153401/pubmed" id="16153401" target="_blank">16153401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15735617">
<a name="15735617"></a>Stempak D, Gammon J, Halton J, et al. Modulation of Celecoxib Pharmacokinetics by Food in Pediatric Patients. <i>Clin Pharmacol Ther</i>. 2005a;77(3):226-228.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/15735617/pubmed" id="15735617" target="_blank">15735617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12426512">
<a name="12426512"></a>Stempak D, Gammon J, Klein J, et al. Single-Dose and Steady-State Pharmacokinetics of Celecoxib in Children. <i>Clin Pharmacol Ther</i>. 2002;72(5):490-497.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/12426512/pubmed" id="12426512" target="_blank">12426512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31022157">
<a name="31022157"></a>"Sulfonamide Cross-reactivity." <i>Med Lett Drugs Ther</i>. 2019;61(1568):44-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/31022157/pubmed" id="31022157" target="_blank">31022157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31937550">
<a name="31937550"></a>Szeto CC, Sugano K, Wang JG, et al. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. <i>Gut</i>. 2020;69(4):617-629. doi:10.1136/gutjnl-2019-319300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/31937550/pubmed" id="31937550" target="_blank">31937550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27569276">
<a name="27569276"></a>Teerawattananon C, Tantayakom P, Suwanawiboon B, Katchamart W. Risk of perioperative bleeding related to highly selective cyclooxygenase-2 inhibitors: a systematic review and meta-analysis. <i>Semin Arthritis Rheum</i>. 2017;46(4):520-528. doi:10.1016/j.semarthrit.2016.07.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/27569276/pubmed" id="27569276" target="_blank">27569276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32189324">
<a name="32189324"></a>Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs. <i>Clin Pharmacol Ther</i>. 2020;108(2):191-200. doi:10.1002/cpt.1830<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/32189324/pubmed" id="32189324" target="_blank">32189324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26943657">
<a name="26943657"></a>Thorell A, MacCormick AD, Awad S, et al. Guidelines for perioperative care in bariatric surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations. <i>World J Surg</i>. 2016;40(9):2065-2083. doi:10.1007/s00268-016-3492-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/26943657/pubmed" id="26943657" target="_blank">26943657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15373844">
<a name="15373844"></a>Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. <i>Contact Dermatitis</i>. 2004;51(2):57-62. doi:10.1111/j.0105-1873.2004.00274.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/15373844/pubmed" id="15373844" target="_blank">15373844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21224324">
<a name="21224324"></a>Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. <i>BMJ</i>. 2011;342:c7086. doi:10.1136/bmj.c7086<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/21224324/pubmed" id="21224324" target="_blank">21224324</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. 2015. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2020">
<a name="FDA.2020"></a>US Food and Drug Administration (FDA). FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic</a>. Published October 15, 2020. Accessed October 20, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17410098">
<a name="17410098"></a>Vadivel N, Trikudanathan S, Singh AK. Analgesic nephropathy. <i>Kidney Int</i>. 2007;72(4):517-520. doi:10.1038/sj.ki.5002251<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/17410098/pubmed" id="17410098" target="_blank">17410098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1321554">
<a name="1321554"></a>Villanueva M, Heckenberger R, Palmér M, Schrör K. Stereospecific and non-stereospecific effects of ibuprofen on human platelet and polymorphonuclear leukocyte functions. <i>Agents Actions Suppl</i>. 1992;37:162-170. doi:10.1007/978-3-0348-7262-1_22<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/1321554/pubmed" id="1321554" target="_blank">1321554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15897671">
<a name="15897671"></a>Viola M, Quaratino D, Gaeta F, et al. Celecoxib tolerability in patients with hypersensitivity (mainly cutaneous reactions) to nonsteroidal anti-inflammatory drugs. <i>Int Arch Allergy Immunol</i>. 2005;137(2):145-150. doi:10.1159/000085794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/15897671/pubmed" id="15897671" target="_blank">15897671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10377455">
<a name="10377455"></a>Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. <i>Proc Natl Acad Sci U S A</i>. 1999;96(13):7563-7568. doi:10.1073/pnas.96.13.7563<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/10377455/pubmed" id="10377455" target="_blank">10377455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12020179">
<a name="12020179"></a>Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. <i>Arch Intern Med</i>. 2002;162(10):1105-1110. doi:10.1001/archinte.162.10.1105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/12020179/pubmed" id="12020179" target="_blank">12020179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10390124">
<a name="10390124"></a>Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. <i>Am J Med</i>. 1999;106(5B):13S-24S. doi:10.1016/s0002-9343(99)00113-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/10390124/pubmed" id="10390124" target="_blank">10390124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30207919">
<a name="30207919"></a>White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. <i>N Engl J Med</i>. 2018;379(11):1060-1070. doi:10.1056/NEJMra1712125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/30207919/pubmed" id="30207919" target="_blank">30207919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16542210">
<a name="16542210"></a>Wyplosz B, Vautier S, Lillo-Le Louët A, Capron L. Tolerance of diclofenac after hypersensitivity to celecoxib and to nabumetone. <i>Br J Clin Pharmacol</i>. 2006;61(4):474. doi:10.1111/j.1365-2125.2005.02576.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/16542210/pubmed" id="16542210" target="_blank">16542210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23741058">
<a name="23741058"></a>Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/23741058/pubmed" id="23741058" target="_blank">23741058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23747642">
<a name="23747642"></a>Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>J Am Coll Cardiol</i>. 2013;62(16):e147-e239. doi:10.1016/j.jacc.2013.05.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/23747642/pubmed" id="23747642" target="_blank">23747642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29667211">
<a name="29667211"></a>Yeomans ND, Graham DY, Husni ME, et al. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. <i>Aliment Pharmacol Ther</i>. 2018;47(11):1453-1463. doi:10.1111/apt.14610<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/29667211/pubmed" id="29667211" target="_blank">29667211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32317121">
<a name="32317121"></a>Zhan M, Doerfler RM, Xie D, et al. Association of opioids and nonsteroidal anti-inflammatory drugs with outcomes in CKD: findings from the CRIC (Chronic Renal Insufficiency Cohort) study. <i>Am J Kidney Dis</i>. 2020;76(2):184-193. doi:10.1053/j.ajkd.2019.12.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/32317121/pubmed" id="32317121" target="_blank">32317121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16707532">
<a name="16707532"></a>Zhang W, Doherty M, Bardin T, et al; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). <i>Ann Rheum Dis</i>. 2006;65(10):1312-1324.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/16707532/pubmed" id="16707532" target="_blank">16707532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-447795">
<a name="447795"></a>Zipser RD, Hoefs JC, Speckart PF, Zia PK, Horton R. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. <i>J Clin Endocrinol Metab</i>. 1979;48(6):895-900. doi:10.1210/jcem-48-6-895<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/celecoxib-pediatric-drug-information/abstract-text/447795/pubmed" id="447795" target="_blank">447795</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12999 Version 665.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
